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SBR                -   Serum Bilirubin   
TCB                -  Transcutaneous Bilirubinometer 
T/ID - Total/ Indirect Bilirubin 
TSB - Total Serum Bilirubin  
UDPGT - Uridine Di Phosphate Glucuronosyl Transferase 
ABSTRACT 
INTRODUCTION: 
 Mostly about 85% of term newborns and premature infants develop jaundice. 
There are various clinically proven reason for this. In this thesis we are mainly focused 
on Cord Bilirubin and its significance in predicting neonatal jaundice in 1st week of 
life. This will help in preventing newborns from developing kernicterus. 
AIM OF THE STUDY: 
To evaluate the predictive value of umbilical cord bilirubin in identifying term 
newborns with ABO /Rh incompatibility for subsequent hyperbilirubinemia in 1st week 
of life. 
METHOD OF STUDY: 
 Prospective clinical study in Tiruneveli Medical College Hospital (TVMCH) 
which is carried out in all consecutive term newborns with ABO /Rh incompatibility 
over a period of 8 months (February 2015 to SePhototherapy ember 2015) duration. 
 The study population was initially followed up clinically by Kramer’s method 
and by transcutaneous bilirubinometer. Newborns identified with jaundice were 
followed up using serial serum bilirubin values. 
 
  
METHOD OF ASSAY - SERUM BILIRUBIN: 
Total serum bilirubin, conjugated bilirubin, unconjugated bilirubin were 
obtained via the calorimetric diazo method. 
RESULTS OF STUDY: 
 Female babies were found to be higher i.e.,62.7% when compared to male babies 
37.% Rh incompatibility is statistically significantly associated with 
PHOTOTHERAPY . Mean total CORD BILIRUBIN is more in Rh incompatibility 
(4.23) when compared to ABO incompatibility (3.86). Mother’s blood group has 
statistical signification with HYPERBILIRUBINEMIA and 
NHYPERBILIRUBINEMIA but it was not seen in baby’s blood group. The mean Hb 
of HYPERBILIRUBINEMIA and NHYPERBILIRUBINEMIA is 15.6 ± 0.7 and 14.2 
± 2 gm/dL respectively and difference between them was statistically significant. The 
mean CORD BILIRUBIN between babies with HYPERBILIRUBINEMIA and 
NHYPERBILIRUBINEMIA was 4 ± 0.5 and 2.3 ± 0.3 mg/dL respectively and 
difference between them was statistically significant. The relationship between total 
CORD BILIRUBIN and SBR was statistically significant 
CONCLUSION 
 Study concludes that the total CORD BILIRUBIN in healthy term newborns 
provides prediction for neonatal jaundice in 1st week of life. The cut off value being 
3.25 with 96.0% of specificity and 96.0% sensitivity. It is also evident that the presence 
of incompatibility in newborns (ABO, Rh) was statistically significant for occurrence 
of high total CORD BILIRUBIN that indicates PHOTOTHERAPY  treatment. 
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INTRODUCTION 
 Babies are called newborns during their first month of life. After birth 
mostly we can witness that babies sleep a lot this is because a lot of changes 
that takes place inside their body system. Mostly about 85% of term newborns 
and premature infants develop jaundice. There are various clinically proven 
reason for this. In this thesis we are mainly focused on Cord Bilirubin and its 
significance in predicting neonatal jaundice. Most babies have mild jaundice. It 
usually gets better or goes away on its own within a week or two without 
causing problems. Generally jaundice should be taken seriously, it may be 
physiological or pathological. In rare cases, if the bilirubin level stays high and 
isn't treated, it can cause brain damage called kernicterus (This term was 
introduced in early 1900s, it refers to the yellow staining of basal ganglia that 
was noticed in newborns died with severe jaundice). This can lead to serious 
lifetime problems too. At times this condition becomes life threatening if it's not 
properly taken care which may lead to hyperbilirubinemia. We are mainly 
concerned about various causes, ill effects as well the prevention mechanism of 
it. 
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DEFINITION 
 Jaundice occurs because your baby's body has more bilirubin level than 
it can get rid of. Bilirubin is a yellow (pigment) substance that's made when the 
body breaks down old red blood cells (RBC's).Generally the life span of RBC is 
120days in adults and whereas the life span of newborn RBCs are 
comparatively lesser. Newborns RBCs are higher in number and shorter in 
span. It’s mainly excreted from the body through urine and stool. When a 
mother is pregnant, her body removes bilirubin from her babies through the 
placenta. After birth, your baby's body must get rid of this bilirubin on its own. 
In most cases, babies have what's called physiologic jaundice. It occurs because 
their organs aren't yet able to get rid of this excess bilirubin on their own. This 
type of jaundice usually appears about 24 hours after birth. It at times gets 
worse by the third or fourth day, and then it goes away in about a week. Many 
babies get jaundice (hyperbilirubinemia) in their first few days of life. In this 
condition the skin and the whites of a baby's eyes appear yellow because of 
excess bilirubin in the blood. 
 In rare cases, jaundice may be caused by other things, such as an 
infection, a problem with the baby's digestive system, or a problem with the 
moms and baby's blood groups or types (ABO/Rh incompatibility). Your baby 
may have one of these problems if jaundice appears less than a day after birth. 
It's always better to check with the levels and take precautionary measures. In a 
normal adult serum bilirubin level ranges from ≤1mg/dL. Whereas adult's 
develop jaundice if the level of serum bilirubin ≥2mg/dL. The same condition 
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when compared to newborns where the serum bilirubin levels ≥7mg/dL they 
develop jaundice. Generally 6.1% of well term newborns have serum bilirubin 
levels ≥12.9mg/dL. 
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EPIDEMIOLOGY 
 Jaundice a most common condition that requires medical attention. In 
order to develop a diagnostic as well management of jaundice in newborns, we 
need to have a clear back ground idea about pathological and non pathological 
factors as well their bilirubin levels. Approximately 60-65% of term infants and 
80-85% of preterm infants develop jaundice. About 10% of breast fed babies 
still have been identified with jaundice within 1month of age. Various risk 
factors that are responsible are Birth weight less than 2500gms or premature 
infants, if previous siblings TSB ≥ 12 mg/dL subsequent sibling is prone to 
jaundice, newborns of mother who have diabetics Section, male child have been 
reported more compared to females, People living at higher altitudes, East 
Asian babies have increased bilirubin compared to others and neonatal infection 
adds risk to hyperbilirubinemia. 
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ETIOLOGY 
Jaundice is generally caused by the excess amount of bilirubin. The 
RBCs Section present in blood help in transport of oxygen and carbon-di-oxide. 
Generally the life span of RBCs in adult 120 days and infants 70-90days.  
 
Senescent RBCs Section break down during which the protein part 
globulin produce bilirubin as end product. Various cause of jaundice have been 
listed as follows: 
PHYSIOLOGICAL JAUNDICE: 
Various factors that bring about physiological jaundice are increased 
RBC volume/kg and reduced RBCs Section life span in newborns, increased 
ineffective erythropoiesis and increased non haemoglobin turnover, increased 
enterohepatic circulation due to increased intestinal β-glucuronidase, decreased 
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uptake of bilirubin from plasma, decreased conjugation due to decreased 
UDPGT activity and decreased excretion of bilirubin by liver. 
NON PHYSIOLOGICAL JAUNDICE: 
Various factors that bring about non physiological jaundice were as 
follows: 
Jaundice occurring ≤ 24 hours of age 
Rise of serum bilirubin ≥ 0.2 mg/dL/hr 
Associated with features of sepsis 
Jaundice more than 8 days in term and more than 14 days in preterm 
CAUSES: 
Sepsis, trauma, TORCH infection, hypothyroidism and infant of diabetic 
mother. 
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BILIRUBIN METABOLISM 
 A normal newborn produces 6-10mg of bilirubin/kg/day where as adults 
3-4mg/kg/day. RBC contains Heme and globin. The senescent RBC releases 
Heme in reticuloendothelial system i.e., the major source of 75% bilirubin. 1gm 
of haemoglobin equal to 34mg of bilirubin. It's found in the blood stream as two 
forms indirect (Unconjugated) bilirubin and direct (conjugated) bilirubin. 
Accelerated release produces hyperbilirubinemia. The balance 25% of bilirubin 
is called Early-labelled bilirubin, which is derived from haemoglobin released 
by ineffective erythropoiesis in bone marrow from other heme proteins in tissue 
and from free heme. 
 
 
 In the senescent RBC haemoglobin is broken into Heme and globin. The 
heme is degraded by heme oxygenase, which releases iron and form carbon 
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monoxide and biliverdin. This biliverdin is then reduced to bilirubin by 
biliverdin reductase. This forms a Bilirubin-Albumin complex. This complex is 
broken down by UDPGT. Further bilirubin enter the liver and gets modified as 
excretable conjugated form in the presence of Glucoronyl-bilirubin transferase 
enzyme. The conjugated bilirubin enters the intestine for excretion as 
Urobilinogen and Stercobilin, at times it may be deconjugated by certain strains 
of bacteria and bilirubin may re-enter the circulatory path. Circumstances like 
increased production of bilirubin, increased enterohepatic circulation, poor 
uptake of liver, enzyme deficit for conjugation (UDPGT- Uridine DiPhosphate 
Glucuronosyl Transferase which is required for conjugation of bilirubin), babies 
who are not fed well with breast milk also were found to have higher risk of 
hyperbilirubinemia, on the other hand breast milk fed babies were found to have 
low levels of intestinal bacteria. Mainly the bilirubin is removed from the body 
through faeces (Stool) as Stercobilin and urine as urobilin which gives the 
colour to faeces and urine.    
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TYPES OF JAUNDICE 
The most common types of jaundice are as follows: 
PHYSIOLOGICAL (NORMAL) JAUNDICE:  
Most newborns have this mild jaundice because their liver is still in the 
phase of maturing. It appears when a baby 2 to 4 days old and disappears by 1 
to 2 weeks of age (≥ 2 mg/dL). In full term infants peak occurs 6-8mg/dL by 3 
to 5 days of age and then falls (≥ 12mg/dL). In premature infants the rise may 
be 10-12mg/dL on 5th day of life (rise in ≥ 15mg/dL). In newborns 
unconjugated bilirubin is not excreted much, whereas the conjugated bilirubin 
excretion is also limited. As a result high serum bilirubin concentration leads to 
physiological jaundice.  
NON PHYSIOLOGICAL JAUNDICE: 
 Jaundice ≤ 24 hours of age. Rise of serum bilirubin that requires 
phototherapy. Rise of serum bilirubin   ≥ 0.2 mg/dL/hour. It's associated with 
features of sepsis. Jaundice more than 8days in term newborn or more than 
14days in preterm newborn. 
BREASTFEEDING JAUNDICE: 
 Jaundice occurs when breastfeeding babies don't get enough breast milk 
from their mother or difficulty in breast feeding persist. It occurs after day 3 of 
life and usually the peak level is more than 12mg/dL in 12 to 13% of breast 
feeding babies. The main factor responsible for breast feeding jaundice is 
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decreased intake of breast milk leads to late bilirubin elimination and increased 
enterohepatic circulation. 
BREAST MILK JAUNDICE: 
This jaundice usually has a late on set and the incident varies form 2-4%. 
In day 4 instead of decrease in serum bilirubin the level may rise to 20-30mg/dL 
by 14days. This may return to normal by 4 to 12 weeks of age. The various 
mechanism responsible for this are unidentified factors that interferes with 
bilirubin metabolism and increased enterohepatic circulation (increased β-
glucuronidase) leads to decreased intestinal bacteria that converts conjugated 
bilirubin to Urobilinoids. 
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RISK FACTORS OF JAUNDICE 
 Several risk factors have been identified for the development of severe 
hyperbilirubinemia in newborns, they have been listed as follows: 
Low gestational age. 
Exclusive breast feeding baby with weight loss or inadequate feeding 
habits. Visible jaundice in ≤ 24 hours of age.  
Isoimmune or other haemolytic diseases.  
Elder sibling with jaundice. Shorter gestation less than 38 weeks.  
Maternal age greater than 25 years.  
Visible Bruising or Cephalohematoma. 
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CLINICAL FEATURES AND EXAMINATION 
 Baby appears yellowish tinged in skin and eyes according to level of 
bilirubin. According to its age, severity and onset it’s further divided into the 
following: 
EARLY STAGE: 
 It occurs between days 1 to 2 and it’s very uncommon. It may be because 
of ABO, Rh, etc.  
ACUTE STAGE: 
 This condition is severe and of sudden onset between 3-10 days. They 
don’t last for longer duration and conditions like poor suckling, high pitched 
cry, lethargy and decreased tone. This is followed by increased tone of extensor 
muscle, fever, irritability and seizure.  Onset of these conditions followed by 
opisthotonus, shrill cry, apnea, seizures and leads to death. 
CHRONIC STAGE: 
 This is a condition developed over a longer period of time, days 14 plus. 
They need proper medical attention for appearances like Athetosis, sensory 
neural deafness, upward gaze defect, dental dysplasia and intellectual defects. 
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KRAMERS RULE AND INTERPRETATION: 
 All newborns should be monitored at subsequent interval of 6-8 hours. 
Kramer's rule provides mechanism for assessing severity of jaundice clinically. 
Generally the progression occurs Cephalocaudal to trunk and then to 
extremities. Keeping these values we can roughly estimate the severity of 
jaundice. Kramer divided the infants into 5 zones and their SBR values as 
follows: 
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Zone 
Head  and 
Neck 
Chest 
Lower body 
and thigh 
Arms and 
legs 
Hands and 
Feet 
SBR mg/dL 5 10 12 15 ≥15 
 
 These visual inspection can only be used as a guide for evaluation of 
jaundice. Visual interpretation may always lead to error. Especially newborns 
with little dark pigmented skin may mislead us. It is just a predictive measure 
for hyperbilirubinemia.  
ASSOCIATED FEATURES IN NEONATAL JAUNDICE: 
 Blood group refers to the entire blood group system consisting of 
erythrocyte antigen. They are controlled by series of genes, either allelic or very 
closely linked genes on a single chromosome.  
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ABO BLOOD GROUPS: 
 This is the most significant blood group system in which antibodies are 
consistently present in serum. They play a vital role in transfusion. These 
antibodies can cause intravascular hemolysis if incompatible blood is 
transfused. Normally a reciprocal relationship exist between ABO 
agglutinogens (antigens) found on surface of RBCs Section and 
isoagglutinogens (antibodies) found in serum.  
 People with O blood group will neither have A nor B antigens on RBC 
and both anti-A and anti-B antibodies were present in serum. A blood group 
people will have antigen An on RBC and anti-B in serum. B blood group people 
will have antigen B on RBC and anti-A in serum. AB blood group people will 
have both antigen A and B on RBC and no antibodies in serum. 
Type of blood 
group 
RBC Antigen 
Serum 
Antibodies 
Occurrences 
A A anti-B 35-40% 
B B anti-A 8-10% 
AB A and B None 3-5% 
O None anti-A and anti-B 40-45% 
  
 Blood groups are inherited from both the parents (Maternal and 
Paternal). The ABO blood group system was controlled by a single gene ABO 
with three types of alleles Iᴬ, Iᴮ and i respectively. The A group is further 
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divided into 20 sub groups like A1, A2. Cis AB is another rare variant, where A 
and B genes are transmitted together from a single parent. 
Parental 
Blood Type 
A B AB O 
A A or O A,B,AB or O A,B or AB A or O 
B A,B,AB or O B or O A,B or AB B or O 
AB A,B or AB A,B or AB A,B or AB A or B 
O O or A O or B A or B O 
 
 ABO incompatibility generally leads to haemolytic diseases in 
newborns. The breakdown of RBC leads to anemia, jaundice and severe cases it 
may lead to death.  
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ABO INCOMPATABILITY IN NEWBORNS: 
 During pregnancy when the mother and child's blood groups are 
mismatching, it leads to the breakdown of RBCs of the baby. If the mother is O 
group, she is prone to this condition. When the baby's blood enters the maternal 
system its recognized as foreign and mother produces antibodies against it. 
Mother blood generally do not mix with the babies, both their circulation have 
been kept separate by placental membrane which serves as a barrier. 
Occasionally like birth, trauma and miscarriage these two blood gets mixed. 
When these antibodies pass through the placental membrane it results in 
breakdown the RBCs of baby. These different blood groups when they come 
into direct contact the antibodies are formed and leads to the breakdown of 
RBCs. This increases the production of bilirubin and leads to jaundice. 
Premature babies are most likely to experience problems because of this ABO 
incompatibility.   
 Even after birth these antibodies will persist for weeks in newborns. The 
cord blood of these babies need to be tested for jaundice. These babies need to 
be closely monitored to rule out hyperbilirubinemia. 
Rh BLOOD GROUPS: 
 The Rh blood group system is one among the prime important type. Rh 
antigens are transmembranous proteins with loops exposed at the surface of 
RBCs. It was named as Rh because it was first discovered form Rhesus 
monkey. According to the presence or absence it's named as Rh+ and Rh- 
respectively. These are determined by two alleles at a single locus, they separate 
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independently of ABO blood group locus. An Rh+ person may be homozygous 
(+/+) or heterozygous (+/-) and express the D antigen, on the other hand Rh- 
individual always found to be homozygous (-/-) with absence of D antigen. 
There are number of Rh antigens like c, C, E and e. These Rh system help to 
avoid the danger of Rh D incompatibility during pregnancy and transfusion. 
 Rh+ cells if infused to Rh- individual evoke antibody response (IgG), 
which is dangerous. During pregnancy Rh incompatibility should be diagnosed. 
Let us assume a Rh- O group mother carrying an Rh+ A, B or AB foetus. 
Mother RBCs will develop antibodies against Rh D antigen. In this case the first 
child may not be affected but subsequent pregnancies these antibodies may 
cross the placenta and attack the RBCs of RH+ baby. A early pregnancy test for 
Rh is done and Rh immunoglobulin shot is given to the mother to prevent Rh 
sensitization.  
MINOR TYPES: 
INDIAN BLOOD GROUP: 
 One of the most recently discovered blood group. It is composed of two 
antigens namely Inᵃ which is of low incidence and Inᵇ of high incidence. These 
antigens are inherited by co-dominant alleles and denatured by certain enzymes. 
Anti Inᵇ has been linked with hemolytic transfusion reactions. Anti Inᵃ has not 
been linked for these reactions. Both antigens has been linked to haemolytic 
disease of newborns. 
 
 
19 
 
LUTHERAN BLOOD GROUP: 
 It is also known as Lu blood group. They have Luᵃ and Luᵇ antigens. 
Anti Luᵃ and Anti Luᵇ are uncommon, which are produced after transfusion or 
pregnancy. They have also been reported only with RBCs stimulation. Mild 
haemolysis has been reported with these antigens and not much of 
consideration. 
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BILIRUBIN VALUES IN NEWBORN 
 In newborns the normal value of bilirubin depends on birth age i.e., in 
hours, premature or full term babies. Normal values of bilirubin provided were 
just for a guideline and they are not same at all places. 
PREMATURE BABIES FULL TERM BABIES 
≤ 24 hours of age - below 8.0 mg/dL ≤ 24 hours of age - below 6.0 mg/dL 
≤ 48 hours of age - below 12.0 mg/dL ≤ 48 hours of age - below 10.0 mg/dL 
3 to 5 days old - below 15.0 mg/dL 3 to 5 days old - below 12.0 mg/dL 
≥ 7 days old - below 15.0 mg/dL ≥ 7 days old - below 10.0 mg/dL 
 
  In full term babies, however if there is a small increase from the above 
levels doesn't mean that immediate treatment and medical attention to be 
provided. Where, high levels of bilirubin in any child above normal needs close 
monitoring and treatment. 
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HAEMOLYTIC DISEASE OF NEWBORN (HDN) 
 Early 1600 to 1900 haemolytic disease of newborn has been a mystery, 
who have been a cause foetal loss temporarily or permanently death. By 1960s 
trails of therapeutic antibodies given to pregnant women's by United Kingdom 
and United States prevented HDN. Today we are more concerned about the 
therapeutic measures and preventing HDN during pregnancy, delivery and 
further babies development.  General cause for haemolytic disease in newborn 
include ABO incompatibility, Rh hemolysis, G6PD deficiency and other minor 
blood group incompatibility. 
MATERNAL ANTIBODIES AND FETAL RISK: 
 Incompatibility of Rh blood typing between mother and foetus is major 
cause of HDN. ABO incompatibility is less severe than Rh with HDN.  
Hemolysis gets triggered mainly by Rh D antigen, whereas other Rh antigens 
play a minor role. When an Rh D-ve mother carries a Rh D+ve baby maternal 
blood is prevented by crossing the barrier placenta. However in first pregnancy 
only during delivery or caesarean, increased bleeding or complicated labor, 
there is a mixing of both blood occur. In this situation mother blood produces 
anti-D against the Rh D antigen. This is retained in her serum as mother gets 
sensitized to Rh D antigens. During first pregnancy it's not effective much, but 
during subsequent pregnancies they lead to destruction of fetal RBCs and lead 
to severe hyperbilirubinemia. If bilirubin level keeps increasing drastically, it 
may enter the brain and cause kernicterus. A condition that leaves permanent 
neurological damage if baby survives. Further prolonged destruction of RBCs 
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Section lead to severe anemia.  The liver and spleen have to over produce RBCs 
to compensate the loss. This leads to hepatosplenomegaly, at times organ 
dysfunction may also occur. As added complication immature RBCs will 
circulate in the blood, which will lead to erythroblastosis fetalis. A complication 
of severe HDN is hydrops fetalis, where the fetal tissues become swollen. This 
may be fatal to the baby in uterus or after birth. 
FIRST PREGNANCY AND SENSITIZATION: 
 When our immune system first encounters an antigen, its considered to 
be foreign and produces immune response. This response produces antibody 
against the antigen, which is called as sensitization.  
 In case of HDN caused by Rh incompatibility, an Rh D -ve mother 
encounters D antigen from her Rh D +ve child or a transfusion etc. On first 
encounter after sensitization the mothers blood produces anti-D. A Direct 
Coombs test from cord blood has confirmed the presence of anti-D in mother 
serum. A small amount of fetal blood entry into mother blood is enough for 
sensitization of mother. This can be brought about by delivery, caesarean, 
haemorrhage during labor, complicated labor, transfusion, etc.  During earlier in 
pregnancy prenatal bleeding or miscarriage may bring about sensitization. 
Certain medical procedure like termination of pregnancy may also bring about 
sensitization. Maternal risk of sensitization is reduced in case of ABO 
incompatibility. In this case the fetal cells are rapidly destroyed by maternal 
anti-A or anti-B or both, this prevent the antigen D exposure. Immediate 
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exchange transfusion followed by phototherapy will prevent the child after 
birth. If Rh immunoglobulin is given to mother within 72 hours of delivery Rh 
sensitization can be prevented and we can also protect the next Rh +ve baby. 
SUBSEQUENT PREGNANCIES AND HDN: 
 Initially formed anti-D is of IgM type which cannot cross the placental 
barrier. In subsequent pregnancies repeated encounter of Rh D antigen produces 
IgG type anti-D. This can easily cross the placental barrier and enter the fetal 
circulation. This anti-D attaches to Rh D antigens and thus destroys fetal RBCs. 
According to hemolysis, HDN may be mild, moderate or high. Mild is within 
tolerable limits, where at birth mild jaundice or anemia is found and gets 
resolved with or without treatment. 
 In case of moderate hemolysis still the level of bilirubin remains low 
during pregnancy as mother placenta removes it from fetal circulatory path. 
After birth the immature liver is not able to metabolise the bilirubin. This leads 
to accumulated increase in bilirubin, which further enters brain and causes 
kernicterus. Monitoring of mother blood serum levels and ultrasound scan at 
regular intervals can be preventive. 
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In case of high levels of prolonged destruction of RBCs lead to sever 
anemia. Fetal anemia can be corrected by blood transfusion, this replaces the 
lysed RBCs Section. The liver and spleen increases the production of RBCs to 
compensate the loss. This leads to hepatosplenomegaly. Immature RBCs enter 
the circulation and leads to erythroblastosis fetalis. Severe complication of 
HDN leads to hydrops fetalis, where the fetal tissue swell up. 
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KERNICTERUS AND HYDROPS FETALIS 
KERNICTERUS 
 Bilirubin a toxic substance to newborns, when it gets elevated in serum 
they lead to hyperbilirubinemia. Kernicterus is a bilirubin induced neurological 
problem that affects the brain of newborns. The extra bilirubin found in the 
circulation gets accumulated as unconjugated bilirubin in the CNS (Central 
Nervous System) / brain tissues. In grey matter the neurological tissue 
undergoes heavy destruction by apoptosis and necrosis which provides 
neurotoxicity. Subsequent damage and scarring of basal ganglia and brain stem 
nuclei occurs. These extracts of yellow substance has been clearly found in 
brain, especially grey matter was proven by autopsy of affected newborns. 
Newborns are mostly affected by hyperbilirubinemia induced kernicterus, 
which is a potentially fatal condition that leaves permanent neurological 
damage in surviving babies. This devastating problem to be focused by frequent 
monitoring of their bilirubin levels, mostly it leads to death. 
CLASSIFICATION: 
 According the characteristic signs and symptom that appear in newborns 
at various stages they are classified as follows: 
I. Acute bilirubin encephalopathy 
II. Chronic bilirubin encephalopathy 
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 Acute bilirubin encephalopathy: 
The signs and symptoms that appear in early stages is termed as acute 
bilirubin encephalopathy. This is further observed under 3 stages of 
newborns as given below 
Stage-1 
On first few days of life where the babies were observed with 
extreme jaundice, poor feeding, lethargy and hypotonia.   
Stage-2 
It occurs on different time and duration where arched back 
with neck hyper extended backwards (hypertonia), seizures, a 
high-pitched cry, retrocollis (back ward arching of neck) and 
opisthotonus (back ward arching of back). Newborns of this 
stage if not treated properly may lead to future serious illness.     
Stage-3 
In newborns aged ≥ 1 week where they have low muscle tone 
(hypotonia)is a typical sign to be monitored. In all these cases the 
bilirubin content has to be rapidly reduced and brought to normal. 
If it's not treated properly it leads to chronic bilirubin 
encephalopathy. 
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I. Chronic bilirubin encephalopathy: 
The signs and symptoms of severe bilirubin induced neurological 
problems that appear over a prolonged period of time is termed as 
chronic bilirubin encephalopathy. The chronic onset leads to various 
clinical manifestations in different stages as follows: 
 Movement abnormalities include Athetosis (Occurs as a result of basal 
ganglia), the upper extremities were more affected than the lower ones. Hearing 
abnormalities include high frequency hearing loss and auditory neuropathy. 
Visual abnormalities include impaired upper and down ward gaze, strabismus 
and nystagmus. Dental abnormalities include Hypoplasia and dysplasia. GERD 
(Gastro esophageal reflux disease) and improper digestion are noted in certain 
cases. It's prone to mental retardation too.  
CAUSES: 
 The exact role of bilirubin in development of kernicterus can be better 
understood if the metabolism of bilirubin is clearly understood. Bilirubin is 
produced when the RBCs are broken down and catabolism of heme occurs. 
During pregnancy the rate of hemolysis is comparatively higher but still 
bilirubin level seems to be low because the placenta removes the bilirubin from 
the fetal circulation. However, after birth drastic increase of bilirubin is noted. 
The newborn's immature liver is not able to metabolise the increased amount of 
bilirubin which gets accumulated in the blood. Increased hemolysis and defect 
in metabolism leads to pile up the accumulation. If the level of bilirubin 
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continues to increase it may even cross the blood-brain barrier and enter the 
brain which cause kernicterus. 
 Newborns cannot completely metabolise the bilirubin for elimination as 
their liver contains UDPGT (Uridine diPhosphate glucuronosyl transferase) 
enzyme which is not active for several months. During pregnancy the mother 
takes up this process where the UDPGT performs a conjugation process called 
glucuronidation. This process adds large amount of sugar to bilirubin and make 
it water-soluble. This complex is easier to excrete through urine and faeces. 
However the serum unconjugated bilirubin level exceeds the binding capacity 
of albumin, unbound lipid-soluble bilirubin crosses the blood-brain barrier. 
Albumin bound bilirubin may also cross the blood-brain barrier if damage has 
occurred because of acidosis, hypoxia, hyperosmolality, asphyxia, or sepsis in 
newborns. In term newborns with hemolysis, bilirubin levels above 20 mg /dL 
(342 μ mol / L) is to be taken care as the incidence of kernicterus was found to 
be associated with these levels and their effects are irreversible. 
 PREVENTION: 
 The increased level of bilirubin should be immediately controlled. 
Screening for hemolysis is highly recommended. If a baby is found with 
jaundice (increased bilirubin levels) or under the risk factor of jaundice, then 
phototherapy, intravenous immunoglobulin administration, or exchange 
transfusion should be recommended. In rare cases combination of Photo 
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therapy, exchange transfusion and intravenous albumin administration saved 
few newborns. 
TREATMENT: 
 Various treatment plans for kernicterus is a mystery to solve. However 
prevention is better than cure. Proper follow-up of newborns and managing the 
bilirubin levels will avoid kernicterus. Reversal of Kernicterus was 
comparatively low. 
HYDROPS FETALIS 
 Hydrops refers to severe edematous (swelling) condition in fetus and 
newborns. When too much of fluid leaves the blood stream and enters the 
tissues hydrops develop. It's also known as abnormal fluid collection in fetal 
organ spaces like abdominal cavity, pericardial effusion, pleural effusion, 
swelling of skin etc. This condition is fatal either intra uterine or immediately 
after birth. 
TYPES OF HYDROPS: 
It is further divided into two types: 
I. Immune hydrops 
II. Non-immune hydrops 
I. Immune hydrops: 
This occurs because of the blood group incompatibility between mother 
and baby. Here the mothers immune system causes the breakdown of fetus 
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RBC's. For example, a mother who has a Rh- Positive who carries Rh- Negative 
baby, she may develop an immune response that destroys the blood cells of 
fetus. A greater prolonged destruction of RBCs lead to severe anemia. The 
liver, spleen, bone-marrow and other organs increase their production of RBCs 
to compensate the loss. This increased production causes hepatosplenomegaly 
and they begin to fail. Kidney, adrenal gland and liver dysfunction may also 
occur. As the heart receives low blood count it may also have to work harder 
and eventually they also fail. The young blood cells called erythroblast get into 
the circulation, giving rise to the name as 'erythroblastosis fetalis'(immune 
hydrops). Rh immunoglobulin a shot given to mother prevent this condition and 
intra uterine fetal death is controlled. 
II. Non-immune hydrops: 
It includes all other diseases and complications that interfere with babies 
concern to manage fluids. Non-immune hydrops is a common type, which is an 
output of various congenital complication and diseases. Severe anemia, 
congenital infections (syphilis, parvovirus), liver diseases, spleen diseases, 
chromosomal abnormalities and birth defects (cystic adenomatoid 
malformation, polycystic kidneys) were causes of non-immune hydrops. 
SYMPTOMS: 
The following are the most common symptoms found in hydrops fetalis: 
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 During pregnancy collection of large amounts of amniotic fluid 
(polyhydramnios), thickened placenta, enlarged (heart, liver, spleen), under 
developed lungs, fluid accumulation around abdomen, heart and lungs have 
been found by ultrasound. 
 After birth the newborn was witnessed with pale colouration, severe 
edema localized or generalized, enlarged (liver, spleen), severe respiratory 
distress, hypoglycaemia, generally swollen and have round abdomen. 
PREVENTION:  
Generally complete family history was worked out as background 
information. Patients medical, social history and physical examination were 
clearly worked out. As a part of diagnostic procedure ultrasound, 
amniocentesis, fetal blood sampling, fetal echocardiogram, prenatal 
ultrasonography, blood test of mother for incompatibility helps greatly to 
prevent hydrops fetalis. 
TREATMENT: 
When the cause for hydrops fetalis is found, like gestational age, extent 
of disease, babies condition and tolerable limits the treatment is planned 
accordingly. If the newborn is found with potentially low blood count, then 
transfusion of blood will be effective. In case of excessive fluid collection 
around lung and abdomen can be removed by a needle. Gene therapy may 
provide therapeutic promise for future. 
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METHODS OF DIAGNOSIS 
KRAMERS METHOD: 
 Direct visual examination of jaundice is not a good measure of bilirubin 
level in blood.  Here the entire fetal body is divided into 5 zones and their 
corresponding SBR provide. This can be used as a guide and not for accuracy. 
TOTAL SERUM BILIRUBIN: 
 Total serum bilirubin can be measured both directly and indirectly. TSB 
level was a good standard examination. However these facilities were available 
in research facilities only. To be precise there were no standard levels to predict 
what level sets a guideline for jaundice. We generally have to go by with 
average values. Only by post mortem evidences it's found that babies with 
lower SBR levels are at risk of kernicterus. 
TRANSCUTANEOUS BILIRUBIN METER: (TCB)  
 Transcutaneous bilirubin levels can be measured with a hand held device 
TCB (Transcutaneous bilirubinometer), which measures bilirubin levels when 
slightly pressed against skin surface.  It is just a screening test.  
ADVANTAGE: 
 One advantage of this method is no need to puncture skin. This 
technique is based on multiple wavelength analysis. Measures serum bilirubin 
independent of skin pigmentation, postnatal age and weight.  
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DISADVANTAGE: 
 It provides an underestimate of TSB. Still the result were not to 
satisfactory levels. Unreliable after phototherapy due to breaching of skin. 
PRECAUTION: 
Check the TSB if TCB ≥ 70th percentile of TSB value for phototherapy. 
TCB ≥ 75th percentile. TCB ≥ 13 mg/dL at follow up or after discharge. 
END TIDAL CARBON MONOXIDE: (ETCoc) 
 It gives the factors that contribute to neonatal jaundice 
(Haemolysis/Conjugation defects) 
Blood grouping and Rh typing of mother and baby. 
Peripheral smear study with reticulocyte count. 
HAEMATOCRIT VALUE: 
 Generally detects polycythemia. It also suggest blood loss from occult 
haemorrhage. 
DIRECT COOMBS TEST: 
 Identification of antibodies on infant RBCs. 
G6PD SCREENING: 
 This may be helpful especially in male infants. G6PD deficiency is more 
common among African American males. Screening parents for G6PD 
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deficiency is helpful in making diagnosis of hyperbilirubinemia. Infants who 
had G6PD deficiency and discharged early have been reported with severe 
hyperbilirubinemia and sequelae.  
HEEL STICK TEST: 
 In this technique blood sample from heel of the baby is collected. A 
sterile lancet is used to puncture the heel, under aseptic condition the blood 
sample derived from baby and stored for analytical purposes.  
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Approach to Clinical Jaundice 
  
Bilirubin ≥12mg/dL 
and infant ≤24-h old 
Coombs' test 
 
Measures bilirubin 
Bilirubin ≤12mg/dL 
and infant ≥24-h old 
 
Positive Coombs' Negative  Coombs' Follow Bilirubin 
Identify Antibody 
Rh, ABO, Kell, etc. 
Direct  Bilirubin 
Direct Bilirubin ≥2; consider: 
Hepatitis, Intrauterine or viral 
infection, Toxoplasmosis, 
Biliary obstruction, Sepsis, 
Galactosemia, α-1-Antitrypsin 
deficiency, Cystic Fibrosis, 
Cholestasis, 
Hyperalimentation, Syphilis 
and Hemorrhage. 
 
Direct Bilirubin ≤2 
Hematocrit 
High 
(Polycythemia) 
Normal or Low 
RBC Morphology 
Reticulocyte count 
• Abnormal: 
• Spherocytosis, 
ElliPhototherapy ocytosis, 
Stomatocytosis, 
Pyknocytosis, ABO 
Incompatability, Red Cell 
Enzyme Deficiency, α 
Thalassemia, 
Drugs(e.g.,Penicillin),DIC 
 
• Normal: 
• Enclosed Hemorrhage, 
Increased Enterohepatic 
circulation, Breast milk, 
Hypothyroidism, Crigler-
Najjar Syndrome, Infant of 
Diabetic Mother, RDS, 
Asphyxia, Infection, 
Gilbert Syndrome, Drugs 
(e.g., Novobiocin), 
Galactosemia(Early) 
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PREVENTION AND TREATMENT 
PHOTOTHERAPY 
 In phototherapy the baby lies in a incubator (enclosed plastic crib).  The 
light emitted with specific wavelength, intensity and proper skin exposure 
makes the bilirubin water soluble.  Bilirubin absorbs visible light with 
wavelength ranging between 400-500nm. Special blue lamps with peak output 
of 425-475nm is found to be effective.   These water soluble bilirubin can be 
easily eliminated with excretion. Phototherapy can be used to prevent 
hyperbilirubinemia with increased TSB levels in newborns as well initial 
therapy in case of severe hyperbilirubinemia. 
TECHNIQUE OF PHOTOCHEMICAL REACTION: 
 Generally it occurs in extra vascular space of skin. The process of 
isomerization changes bilirubin into water soluble isomers, that's passed out 
without getting stuck in liver. The natural isomer of UCB (4Z, 15Z) is 
converted to 4Z, 15E polar isomer that gets diffused into circulation and 
excreted into the bile. If the excretion is slow the photo isomer is converted 
back to UCB and reabsorbed from the gut. Even at cases bilirubin level remains 
same, their toxicity has been reduced by presence of these photo isomers about 
20% at equilibrium.  
Structural isomerization consist of intramolecular crystallization of 
bilirubin, which results in the formation of lumirubin. Lumirubin constitutes 2 
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to 6 % of TSB concentration. Conversion of bilirubin to lumirubin is 
irreversible. It is excreted through bile and urine. Lumirubin is responsible for 
therapeutic effect of phototherapy in lowering bilirubin levels.  
INDICATIONS OF PHOTOTHERAPY: 
 The phototherapy technique is used when bilirubin level increases and 
proves fatal to infants. During last few years, autopsy has proved that immature 
infants were at risk of bilirubin encephalopathy at lower TSB levels than mature 
infants. Newborns with haemolytic disease and increased serum bilirubin levels 
were subjected to phototherapy. On special occasion like ELBW infants, 
severely bruised infants and slight increase in TSB levels were immediately 
provided with phototherapy as prophylactic measure. Test for bilirubin-albumin 
binding or unbound bilirubin ration is used in certain cases. If the indirect 
bilirubin levels were not high, recommendation of phototherapy may lead to 
"Bronze Baby" syndrome. Exchange transfusion more safer than phototherapy.   
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TYPES OF PHOTOTHERAPY: 
 Newborns with jaundice were treated with various light spectrum called 
phototherapy. Various types of phototherapy as follows: 
BLUE LIGHT: 
 Special blue lamps with wave length output 425-475 nm, is most 
effective in treatment of neonatal jaundice. Generally newborns with TSB 
levels greater than 20mg/dL were treated with this blue light. The results were 
observed every 2, 4, 6, 8 12, 24, 36 and 48 hours. Final result proved 
satisfactory that bilirubin levels get reduced. 
WHITE LIGHT: 
 Generally white lights are less effective compared to others. Their wave 
length varies from 380-700nm. Decreasing the distance between lamp and the 
baby increases effectiveness.   
GREEN LIGHT: 
 This type of light is not in common use because the time and duration of 
exposure is comparatively longer to have significant results. 
LIGHT BANKS: 
 It consist of alternating special blue and day light. Fluorescent lights are 
more effective compared to normal ones.  
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SPOT PHOTOTHERAPY: 
 Used in newborns under radiant warmers. Here the baby is place on 
fiberoptic blanket overhead with quartz halide white light with blue spectrum 
output. 
DOUBLE PHOTOTHERAPY: 
 In this blue green spectrum of light has been used which proves to be 
more useful. The baby lies on fiberoptic blanket, where the phototherapy lights 
were found to be overhead. Concurrent use of two or more phototherapy units 
for same baby is made possible. Newborns with high TSB levels use this type.   
DOS AND DONTS: 
Newborn are kept naked to ensure that full body is exposed to 
phototherapy. Eye padding should be done to avoid retinal damage. Distance 
between the newborn and the baby should be less than 20 inches. Newborn 
should be placed at the centre of the circle of light, to ensure full effect of 
phototherapy. Basic fluid requirement should be met by frequent feeding or it 
may lead to dehydration. Phototherapy is discontinued when the TSB level falls 
less than 1.5-3mg/dL of the initial value. 
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SIDE EFFECTS OF PHOTOTHERAPY: 
Various side effects include skin rash, insensible water loss, retinal 
damage, dehydration or diarrhoea, difficulty in maintaining Homeostasis 
(Hypothermia/Hyperthermia), redistribution of blood flow leading to PDA 
(Patent Ductus Arteriosis) in preterm newborn, hypocalcemia, tanning of skin/ 
Bronze baby syndrome, sister chromatids exchanges or breaking of DNA strand 
occurs and reduction of tryptophan in aminoacid solution. 
EXCHANGE TRANSFUSION (ET) 
 When phototherapy fails to control bilirubin neurotoxicity, exchange 
transfusion stands as second life saving treatment. It is a process of removing 
haemolysed and antibody coated erythrocytes and replacing it with donor blood. 
This removes blood toxins and certain blood components, as well replacing it 
with adequate blood. As a prophylactic treatment early exchange transfusion 
was performed which avoids fatal results.   
 Generally early exchange transfusion is done in anemia with cord 
haemoglobin ≤ 11gm/dL, elevated cord bilirubin ≥ 4.5mg/dL or both. Severe 
increase in TSB level more than 1mg/dL/hr and ≥ 0.5mg/dL/hr with moderate 
anemia, when bilirubin level ≥ 20 mg/dL or if there is progression of anemia 
inspite of controlled bilirubin values is an indication for exchange transfusion.  
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Blood volume used in exchange transfusion for term infants 80ml/kg (1 
x circulating blood volume), is called single volume transfusion. Blood volume 
used in exchange transfusion for newborn infants 2 x 80 ml/kg is called double 
volume transfusion. This replaces about 87% of newborns blood with new 
blood. 
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BLOOD USED FOR TRANSFUSION: 
Fresh whole blood (≤ 7 days) irradiated and FFP collected in CPD is 
used. In Rh incompatibility O -ve cross matched blood against mother is used. 
In ABO incompatibility O -ve or Rh compatible and cross matched with mother 
and infant is used. Blood should not contain sensitizing antigen and cross 
matched with mother for other isoimmune hemolytic disease. In non immune 
disease blood is typed and cross matched against newborn. 
TECHNIQUE OF EXCHANGE TRANSFUSION: 
Done in newborn placed under warmer with vital monitoring. Newborns 
extremities has to be restrained carefully. Appropriate blood volume should be 
calculated for newborn before transfusion. Blood should be pre warmed to 37 
degree Celsius. Strict aseptic condition is maintained umbilical vein line is 
secured. Do exchange transfusion by pull push technique in aliquots of 5ml for 
≤ 1.5 kg, 10ml for ≥ 1.5 -2.5 kg, 15ml for ≥ 2.5-3.5 kg and 20ml for ≥ 3.5kg 
was recommended. General time period recommended for exchange transfusion 
is 1 hour. Every 4 hours of interval SBR levels to be checked after transfusion 
and phototherapy is continued. 
COMPLICATIONS OF PHOTOTHERAPY: 
Metabolic complication include Hypocalcemia, hypomagnesaemia, 
hypoglycaemia and hyperkalemia. Acid base imbalance includes late metabolic 
alkalosis (If the baby has healthy liver), acidosis (If the baby is sick and not able 
to metabolise citrate). Iatrogenic causes are vessel perforation, embolization, 
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thrombosis, infarction, arrthymia and volume over load. Thrombocytopenia and 
decreased clotting factor induced bleeding. Blood born infections are sepsis, 
AIDS, CMV, HIV and malaria. Graft Versus host disease are prevented by 
using irradiated blood. 
RECENT MODALITIES: 
IVIG : 
 In Rh and ABO incompatibility administration IVIG is found to 
significantly reduce the need for exchange transfusion. Recommended dose 
varies from 500-1000mg/kg. This can be used in combination with intensive 
phototherapy. IVIG was not much useful if the newborn was anaemic (Hb ≤ 
10mg/kg)   
ORAL PHENOBARBITONE: 
 It reduces the bilirubin content of blood by inducing microsomal 
enzymes increases bilirubin conjugation and excretion. 
ORAL AGAR: 
 It's given to the newborns with bilirubin values ≥ 15 mg/dL (breast and 
formula fed newborns) to reduce the bilirubin level in blood. Generally the 
mechanism of action is by decreasing enterohepatic circulation.  
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METALLOPROTO PORPHYRINS: 
 Tin and zinc were most commonly used. Mechanism of action is by 
competitive inhibition of heme oxygenase. They are used to treat Coombs +ve 
ABO incompatibility and Crigler Najjar type-1 patient with hyperbilirubinemia.   
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AIMS AND OBJECTIVE 
 To evaluate the predictive value of umbilical cord bilirubin in identifying 
term newborns with ABO /Rh incompatibility for subsequent 
hyperbilirubinemia in 1st week of life. 
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METHOD OF STUDY: 
 Prospective clinical study in Tiruneveli Medical College Hospital 
(TVMCH) which is carried out in all consecutive term newborns with ABO /Rh 
incompatibility over a period of 8 months (February 2015 to September 2015) 
duration. 
 The study population was initially followed up clinically by Kramer’s 
method and by transcutaneous bilirubinometer. Newborns identified with 
jaundice were followed up using serial serum bilirubin values. 
METHOD OF ASSAY - SERUM BILIRUBIN: 
 Total serum bilirubin, conjugated bilirubin, unconjugated bilirubin were 
obtained via the calorimetric diazo method. 
3ml of cord venous blood was taken in a sterile syringe, put in clean capped 
tube and sent immediately to the hospital lab. Serum was used for analysis most 
importantly samples were protected from light during processing and storage. 
The haemolysed samples were then excluded. 
INCLUSION CRITERIA: 
All consecutively born babies in Tirunelveli Medical College Hospital 
irrespective to mode of delivery and gender were included. Term newborns with 
gestational age of 36-40 weeks were included. APGAR score of over 7 at the 
first minute and 10 at fifth minute of life is taken. Absence of significant illness 
or major congenital malformation. 
47 
 
EXCLUSION CRITERIA:         
Term newborns with significant illness like sepsis, respiratory distress 
syndrome, infant of diabetic mother, asphyxia that could aggravate 
hyperbilirubinemia. Low birth weight newborns (≤ 2kg). 
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REVIEW OF LITERATURE 
MEASUREMENT OF BILIRUBIN: 
  There is no difference between capillary and venous blood sampling for 
bilirubin.  Bhutani et al used capillary and venous sampling in his studies. TcB 
(Transcutaneous bilirubinometer) is unreliable after phototherapy or notifiable 
colour changes in skin and its thickness. It can be only used as screening tool or 
in predicting low levels of serum bilirubin. 
TCB AND TSB: 
  Maisels et al used strategies for determining bilirubin when TSB 
measurement is indicated. Measurement of TSB should be performed on 
following conditions; 
1. TCB value ≥ 70% of TSB level 
2. TCB more than 75th percentile on Bhutani namogram 
3. TCB value ≥ 30 mg/dL at follow up or discharge 
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ASSOCIATION WITH RATE OF CONFIGURATIONAL 
ISOMERISATION IN PHOTOTHERAPY  WITH HB LEVEL: 
 In phototherapy, formation of photoisomers i.e., Z to E form is 
significant after only 15mts. Mreihil K et al, has found that initial rate of 
isomerization is indirectly proportional to the HB level. 
ASSOCIATION OF PHOTOTHERAPY AND HIGH LEVEL OF SERUM 
BILIRUBIN: 
 Adelia and Cancciacao 2004 studies state that phototherapy was 
significantly associated with high levels of CORD BILIRUBIN values i.e., 2.1 
± 0.46 mg/dL and level with no phototherapy is 1.75 ± 0.46 mg/dL. 
LEVEL OF SERUMBILIRUBIN AND JAUNDICE: 
  Alpay et al, in his study used serum bilirubin level of 120 μ mol/L in 
predicting development of neonatal jaundice and levels that has been less than 
120 μ mol/L in first day didn't develop any symptoms related to 
hyperbilirubinemia. This study was supported by Stevenson et al. 
PRETERM NEONATES WITH JAUNDICE AND VITAMIN 
SUPPLEMENTATION: 
Ballin et al, states that high vitamin C supplementation leads to heins 
body hemolytic anemia in preterm infants. Doyle et al, work didn't support the 
above study. Bass et al, state that administration of vitamin C is safe but not 
associated with hemolysis. Ojo et al, stated decreased vitamin E in term 
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newborn is associated with increase in bilirubin level and development of 
jaundice. 
ASSOCIATION OF CORD BILIRUBIN AND GENDER: 
 In a specific study correlation exist between levels of cord bilirubin and 
jaundice development in 1st week of life. Study population comprises of 50 
males and 44 females which includes both term and preterm. In preterm cord 
bilirubin is found to be higher in male gender. In term babies cord bilirubin is 
equal in both genders i.e., there was no satisfactory significant difference 
between them. 
The above study matched with Amar et al, Rostami and Mehrabi. This 
study was disagreed with Rudy et al. 
ASSOCIATION OF CORD BILIRUBIN WITH BIRTH WEIGHT AND 
GESTATIONAL AGE: 
 Matthias et al in his study concluded that CORD BILIRUBIN is 
negatively correlated with gestational. Adelia and Canceicao in his study 
proved that there was no correlation between CORD BILIRUBIN and Birth 
weight.  
ASSOCIATION OF CORD BILIRUBIN WITH MODE OF DELIVERY: 
 Rostami, Mehrabi and Amar et al stated there was no significant 
difference between normal delivery and caesarean section. 
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ASSOCIATION OF CORD BILIRUBIN WITH BLOOD GROUPS: 
 In one study ABO incompatibility was found in 13.8% of all study group 
and 3.2% only with Rh incompatibility. This indicates the mean CORD 
BILIRUBIN value is significant among ABO incompatibility compared to 
negative ones in both groups. 
Adalia and Canceicao stated that no significant difference in CORD 
BILIRUBIN between blood group incompatibility. 
CUT OFF POINTS OF CORD BILIRUBIN IN TERM AND PRETERM:  
 Rudy et al used ROC analysis and states that CORD BILIRUBIN more 
than 2.5 mg/dL had high specificity and sensitivity. Amar et al found in his 
studies that CORD BILIRUBIN more than 2 mg/dL had high sensitivity and 
this critical bilirubin level had very high negative predictive value and fairly 
low positive predictive value. 
 Rostami and Meharabi in their study figured out that CORD BILIRUBIN 
more than 3 mg/dL is not a useful predictor of jaundice. Suresh and Clark stated 
that CORD BILIRUBIN could predict the development of jaundice in term 
newborn. Rataj et al from his studies concluded CORD BILIRUBIN ≥ 2.5 
mg/dL had probability of 89% possibility of development of jaundice. 
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STATISTICAL ANALYSIS 
During the first week of neonatal, the incidence of Hyperbilirubinemia 
was classified as positive and the others were treated as negative. The 
measurable variables were analyzed and interpreted between them by the 
student’s t test and the ordinal and categorical variables between them were 
interpreted by Chi- square (χ2) test. The risk factors were interpreted by binary 
logistic regression. The predictive value of incidence was estimated by the ROC 
curve. The statistical procedures were performed with the help of an appropriate 
statistical package or manually. The P-values less than 0.05 (P<0.05) was 
considered as statistically significant. 
  
53 
 
RESULTS: 
 The study subjects of 150 newborn babies were observed for 1week and 
those who have developed Hyperbilirubinemia and they were classified as 
HYPERBILIRUBINEMIA and the remaining babies were treated as ordinary 
babies. The various analysis and interpretations were made by comparing the 
two groups. The groups were described according to their Mothers age, 
Gestational age, parity mode of delivery mother’s blood group and the 
neonate’s blood group. 
Table:1. Age of mothers compared between the   
HYPERBILIRUBINEMIA and NONHYPERBILIRUBINEMIA: 
Mothers’ 
age group 
NONHYPERBILIR
UBINEMIA 
HYPERBILIRUBI
NEMIA 
Total 
Frequency % Frequency % Frequency % 
20-24 11 22.0 26 26 37 24.7 
25-29 38 76.0 42 42 80 53.3 
30-34 1 2.0 27 27 28 18.7 
35-39 0 0.0 5 05 5 3.3 
Total 50 100.0 100 100.0 150 100.0 
Mean ±SD 25.9±2.1 27.2±4.1  
Significance P<0.05  
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In the above the mean age NONHYPERBILIRUBINEMIA(Non 
Hyperbilirubinemia) neonatal  Mothers was   25.9±2.1 years. The mean age of 
HYPERBILIRUBINEMIA(Hyperbilirubinemia)  was 27.2±4.1 years. The 
difference between the above means was statistically significant, (P<0.05).   
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RELATIONSHIPS OF MATERNAL AND PERINATAL 
CHARACTERISTICS WITH NONHYPERBILIRUBINEMIA AND 
HYPERBILIRUBINEMIA:  
Table-2: The association between the parity with the 
NONHYPERBILIRUBINEMIA  and  HYPERBILIRUBINEMIA: 
Par
ity 
NONHYPERBILIRU
BINEMIA 
HYPERBILIRUB
INEMIA 
Tot
al 
 
χ2 
d
 
f 
signific
ance 
No % No % No % 
1 43 86.0 53 53.0 96 64 
15.9
04 
2 
P<0.00
1 
2 6 12.0 36 36.0 42 28 
3 1 2.0 11 11.0 12 8.0 
Tot
al 
50 100.0 100 100.0 
15
0 
10
0.0 
 
0
20
40
60
80
100
120
1 2 3 Total
NHBR %
HBR %
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In the above table the association between the parity of mother with the 
babies of NONHYPERBILIRUBINEMIA and HYPERBILIRUBINEMIA. The 
results revealed that the primy para neonates were associated with 
NONHYPERBILIRUBINEMIA and the multi para neonates were associated 
with HYPERBILIRUBINEMIA. The relationship was statistically very highly 
significant (p<0.001).  
Table-3: Mode of deliveries and association with  
NONHYPERBILIRUBINEMIA  and  HYPERBILIRUBINEMIA: 
Mode  
of  
Delivery 
NONHYPERBILIR
UBINEMIA 
HYPERBILIRU
BINEMIA 
To
tal 
 
χ2 
d
f 
signifi
cance 
No % No % No % 
LABOU
R 
NATUR
AL  
21 42.0 39 39.0 60 
40.
0 
0.1
25 
1 P>0.05 
CAESA
REAN 
SECTIO
N 
29 58.0 61 61.0 90 
60.
0 
Total 50 100.0 100 100.0 
15
0 
10
0.0 
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The table -3 Shows that there was no statistically significant association 
(P>0.05). 
  
0
20
40
60
80
100
120
LN CS Total
NHBR %
HBR %
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Table-4: The association between the gender of neonates with 
NONHYPERBILIRUBINEMIA and HYPERBILIRUBINEMIA: 
G
en
d
er
 
NONHYPERBILIRU
BINEMIA 
HYPERBILIRUBI
NEMIA 
Total 
χ2 
d
f 
signific
ance 
No % No % No % 
Male 20 40.0 36 36.0 56 
37.
3 
0
.2
2
8
 
1 P>0.05 
Fema
le 
30 60.0 64 64.0 94 
62.
7 
Total 50 100.0 100 100.0 
15
0 
100
.0 
 
 
The NONHYPERBILIRUBINEMIA and HYPERBILIRUBINEMIA did 
not have any significant association with the gender of the baby (P>0.05). 
0
20
40
60
80
100
120
Male Female Total
NHBR %
HBR %
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Table-5. Mothers’ blood group associated with incidence of 
HYPERBILIRUBINEMIA and NONHYPERBILIRUBINEMIA: 
B
lo
o
d
 g
ro
u
p
 
NONHYPERBILIRU
BINEMIA 
HYPERBILIRUBI
NEMIA 
Total 
χ2 
d
f 
Signifi
cant 
No % No % 
N
o 
% 
A- 1 2.0 9 9.0 10 6.7 
3
7
.7
1
1
 
6 
P 
<0.001 
A+ 17 34.0 3 3.0 20 13.3 
AB
+ 
4 8.0 8 8.0 12 8.0 
B- 0 0.0 11 11.0 11 7.3 
B+ 12 24.0 15 15.0 27 18.0 
O- 2 4.0 13 13.0 15 10.0 
O+ 14 28.0 41 41.0 55 36.7 
Tot
al 
50 100.0 100 100.0 
15
0 
100.
0 
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The Mothers’ blood groups A-, B-, O- and O+ were associated with 
HYPERBILIRUBINEMIA neonates and A+ and B+ were associated with 
NONHYPERBILIRUBINEMIA. The associations were statistically very highly 
significant (P<0.001).  
  
0
20
40
60
80
100
120
A- A+ AB+ B- B+ O- O+ Total
NHBR %
HBR %
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Table-6. Neonates’ blood group associated with incidence of 
HYPERBILIRUBINEMIA and NONHYPERBILIRUBINEMIA: 
B
lo
o
d
 g
ro
u
p
 NONHYPERBILIR
UBINEMIA 
HYPERBILIRUBI
NEMIA 
Total 
χ2 
d
f 
Signifi
cant 
No % No % No % 
A- 1 2.0 2 2.0 3 2.0 
5
.9
2
2
 
6 P>0.05 
A+ 17 34.0 28 28.0 45 30.0 
AB+ 0 0.0 7 7.0 7 4.7 
B- 1 2.0 2 2.0 2 1.3 
B+ 19 38.0 46 46.0 46 30.7 
O- 1 2.0 1 1.0 1 0.7 
O+ 11 22.0 14 14.0 14 9.3 
Total 50 100.0 100 100.0 
15
0 
100.
0 
  
 
0
20
40
60
80
100
120
A- A+ AB+ B- B+ O- O+ Total
NHBR %
HBR %
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The neonates blood groups were not significantly associated with 
NONHYPERBILIRUBINEMIA and HYPERBILIRUBINEMIA (P>0.05). 
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Table-7: The association between the ABO incompatibility with 
NONHYPERBILIRUBINEMIA and HYPERBILIRUBINEMIA: 
ABO 
incom
pat.  
NONHYPERBILIRU
BINEMIA 
HYPERBILIRUB
INEMIA 
Total χ
2 
d
f 
signifi
cance 
No % No % No % 
Nil 40 80.0 64 64.0 
10
4 
69.3 
4
.0
1
3
 
1 
P 
<0.05 
Yes 10 20.0 36 35.0 46 30.7 
Total 50 100.0 100 100.0 
15
0 
100.
0 
 
The ABO incompatibility shown in the above table had associated with 
the HYPERBILIRUBINEMIA (35%) and nil associated with 
NONHYPERBILIRUBINEMIA (80%). These associations were statistically 
significant (P<0.05). 
0
20
40
60
80
100
120
Nil Yes Total
NHBR %
HBR %
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Table-8: The association between the Rh incompatibility with 
NONHYPERBILIRUBINEMIA and HYPERBILIRUBINEMIA: 
Rh 
incom
pat.  
NONHYPERBILIR
UBINEMIA 
HYPERBILIRU
BINEMIA 
To
tal 
 
χ2 
d
f 
signific
ance 
No % No % No % 
Nil 50 100.0 73 73.0 
12
3 
82.
0 
14.
685 
1 
P<0.00
1 
Yes 0 0.0 27 27.0 27 
18.
0 
Total 50 100.0 100 100.0 
15
0 
10
0.0 
 
 
The Rh incompatibility shown in the above table had associated with the 
HYPERBILIRUBINEMIA (27%) and nil associated with 
0
20
40
60
80
100
120
Nil Yes Total
NHBR %
HBR %
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NONHYPERBILIRUBINEMIA (100%). These associations were statistically 
very highly significant (P<0.05). 
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COMPARISON OF PERINATAL CHARACTERISTICS NBHR AND 
HYPERBILIRUBINEMIA: 
 The perinatal characteristics of neonatal such as gestational age, birth 
weight, Hb,   Apgar scores 1M and 5M were compared between 
NHYPERBILIRUBINEMIA and HYPERBILIRUBINEMIA. 
Table:9. Comparison of perinatal characteristics between 
NONHYPERBILIRUBINEMIA and HYPERBILIRUBINEMIA: 
Variable 
NONHYPER
BILIRUBINE
MIA, n=50 
HYPERBILI
RUBINEMIA
, n=100 
Difference 
b/w means 
‘t’ df Significance 
Mean SD Mean SD 
GA 36.5 0.5 36.6 0.5 0.1 1.874 148 P>0.05 
BW 2.6 0.3 2.7 0.3 0.1 0.278 148 P>0.05 
HB 14.2 2.1 15.6 0.7 1.4 5.928 148 P<0.001 
Apcar1m 7.2 0.4 7.1 0.3 0.1 1.527 148 P>0.05 
Apcar5 m 8.16 0.4 8.18 0.4 0.02 0.303 148 P>0.05 
 In the above variables except  HB, the others did not differed 
significantly. The mean HB of NONHYPERBILIRUBINEMIA was 
14.2±2.1gms/dl and the same of HYPERBILIRUBINEMIA was 15.6 
±0.7gms/dl. The difference between them was statistically very highly 
significant (P<0.001). 
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CORD BILIRUBIN CHARACTERISTICS: 
Table:10. Comparison of total CORD BILIRUBIN and SBR between 
NONHYPERBILIRUBINEMIA and HYPERBILIRUBINEMIA at birth: 
Total 
NONHYPERB
ILIRUBINEMI
A, n=50 
HYPERBILI
RUBINEMIA
, n=100 
Difference 
b/w means 
‘t’ df Significance 
Mean SD Mean SD 
CORD 
BILIRU
BIN 
2.3 0.3 4.0 0.5 1.7 21.357 148 P<0.001 
SBR 2.6 0.4 8.8 2.6 6.2 16.486 148 P<0.001 
 
The mean CORD BILIRUBIN total of two groups was 2.3±0.3 and 4.0 ± 
0.5. The difference was statistically significant (P<0.001). Similarly the mean 
difference between them was statistically very highly significant (P<0.001).  
  
68 
 
Table-11: Relationship between total CORD BILIRUBIN and SBR: 
Variables n r significance r2 % of  r2 
Total CORD 
BILIRUBINXSBR 
150 0.861 P<0.001 0.741 74.1 
 
The relationship between Total CORD BILIRUBIN and SBR was 
statistically very highly significant (P<0.001).  
Regression equation for estimating the total SBR through total CORD 
BILIRUBIN: 
Fig-1:Regression Curve of relation between CORD BILIRUBIN total with 
SBR total. 
 
Regression equation: SBR (T)= 3.513CORD BILIRUBIN(T) – 5.343. 
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PREDICTION OF CORD BILIRUBIN (T) CUT OFF VALUE: 
The variables such as CORD BILIRUBIN total, gestational age, gender, 
ABO incompatibility and Rh incompatibility were inter related variables in 
predicting the cut point of CORD BILIRUBIN total. The Logistic regression 
results are tabulated in table-12. 
Table-12: Logistic regression on GA,SEX, ABO, Rh and CORD 
BILIRUBIN Total. 
Variable B SE Wald df P EXP (B) 
GA 2.609 1.919 1.849 1 0.174 13.587 
Sex (M) 3.217 5.367 0.359 1 0.549 24.949 
ABO -2.149 1.788 1.444 1 0.229 4.117 
Rh -19.122 5191.355 0.000 1 .093 0.000 
CORD 
BILIRUBIN 
Tot 
11.447 4.342 6.949 1 .008 93591.7 
Constant -126.134 76.972 2.685 1 .101 .000 
In the above table -12 Except  CORD BILIRUBIN total all variables are 
not statistically significant (P>0.05). Hence the logistic regression was applied 
only for CORD BILIRUBIN total with NONHYPERBILIRUBINEMIA and 
HYPERBILIRUBINEMIA. 
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Table-13:Logistic Regression on CORD BILIRUBIN Total 
Variable B SE Wald df P EXP (B) 
CORD 
BILIRUBIN 
Total 
9.197 2.950 9.716 1 .002 9864.989 
Constant -28.666 9.616 8.888 1 .003 0.000 
 
Fig-2: Roc Curve for total CORD BILIRUBIN cut point. 
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Area Under the Curve 
Test Result Variable(s): CORD BILIRUBINTOTAL 
Area 
Std. 
Errora 
Asymptotic Sig. 
Asymptotic 95% Confidence Interval 
Lower 
Bound 
Upper Bound 
.996 .003 .000 .990 1.000 
 
The curve estimation was done statistically significant (P<0.00). The 
diagonal segment would give the predictive value of CORD BILIRUBIN Total 
for HYPERBILIRUBINEMIA. 
Table-14: Predictive value of HYPERBILIRUBINEMIA: 
CORD 
BILIR
UBIN 
Level 
HYPERBILIRU
BINEMIA 
NHYPERBILIR
UBINEMIA 
Sensit
ivity 
Specif
icity 
PP
V 
N
P
V 
You
den 
Inde
x 
≥3.25 99 2 
96.0% 96.0% 
98
.0 
97
.9 
0.95
9 
<3.25 1 48 
Total 100 50 
  
The above table -13 states the cut off value is 3.25 of CORD 
BILIRUBIN Total. At this point the sensitivity is 96.0% and specificity is 
96.0%and the Youden index is highest (0.959). 
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Table-15.Comparison of Total Serum Biliriubin (SBR) in different days: 
Day n Mean SD Min Max ‘F’ Significance 
0 50 2.3 0.3 1.9 3.5 
177.38 
Significant with all days 
1st  34 4.4 0.5 3.2 5.6 Significant with all days 
2nd  41 3.9 0.4 3.2 4.8 Significant with 0&1st 
day. 2nd, 3rd and 4th days 
were not significant. 
3rd  20 3.6 0.3 3.2 4.3 
4th  5 3.7 0.7 3.3 3.9 
Total 150 3.4 0.9 1.9 5.6  
 
The SBR total of NONHYPERBILIRUBINEMIA was statistically 
significantly lesser than the other days. Similarly, the 1st day 
HYPERBILIRUBINEMIA total SBR was significantly greater than the other 
days. The other three days total SBR were significantly lesser than the 1st day.     
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Table-16: Comparison of HYPERBILIRUBINEMIA, from 12th to 24th 
hour, 24th hour to PHOTOTHERAPY  transfusion and 12th hour to 
PHOTOTHERAPY  transfusion. 
Pair 
Pre Post Difference 
‘t’ df Signifi 
Mean SD Mean SD Mean SD 
12th to 24th 12.1 9.0 10.2 1.1 1.9 9.1 2.068 99 P<0.05 
24th hour to 
PHOTOTHERA
PY  
10.2 1.1 8.4 1.3 1.8 0.7 25.334 99 P<0.001 
12th hour to 
PHOTOTHERA
PY  
12.1 9.0 8.4 1.3 3.7 9.1 4.007 99 P<0.001 
  
The reduction of reductions of total SBR with in the 
HYPERBILIRUBINEMIA were statistically significant. 
Table-17: Association between ABO incompatibilities with 
PHOTOTHERAPY  transfusion: 
ABO 
PHOTOTHERAPY  transfusion 
χ2 df significance 
No % Yes % Total % 
No 93 67.4 11 91.6 104 69.3 
2.025 1 P>0.05 Yes 45 32.6 1 8.4 46 30.7 
Total 138 100.0 12 100.0 150 100.0 
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The above table shows that there was no significant association between 
ABO Incompatibilities and PHOTOTHERAPY  transfusion (P>0.05) 
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Table-18: Association between Rh incompatibilities with 
PHOTOTHERAPY  transfusion: 
Rh 
PHOTOTHERAPY  transfusion 
χ2 df significance 
No % Yes % Total % 
No 122 88.4 1 8.3 123 82.0 
42.685 1 P<0.001 Yes 16 11.6 11 91.7 27 18.0 
Total 138 100.0 12 100.0 150 100.0 
 
The above table -17 shows the association between Rh incompatibilities with 
PHOTOTHERAPY  transfusion. The results revealed that the 
PHOTOTHERAPY  transfusion very strongly associated with Rh 
incompatibilities (P<0.001). 
Table-19:Total SBR of HYPERBILIRUBINEMIA in difference days: 
Day n Total SBR Range 
Mean SD 
1st  100 8.8 2.6 6.5-15.2 
2nd  66 11.3 1.0 9.4-13.8 
3rd  25 12.3 0.7 11.4-13.8 
4th  5 13.5 0.5 13.1-14.2 
    
The mean total SBR was in increasing trend. 
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DISCUSSION 
  Neonatal hyperbilirubinemia is one of the most common clinical entity 
that we come across with newborns. Mostly 85% of term and pre term 
newborns develop jaundice. Prediction of neonatal jaundice is more important 
as severe jaundice (Kernicterus) can occur in a healthy term baby with no 
clinically apparent jaundice in 24 hours. In this study we have arrived to a 
predictive value of cord bilirubin for neonatal jaundice in 1st week of life.  
  Our study population contains 150 newborns in which 100 newborns 
developed jaundiced and 50 newborns have no jaundice. Out which 37.3% were 
male baby and 62.7% were female baby. In this study we found that 
HYPERBILIRUBINEMIA did not have any significant association with the 
gender of the baby (P value more than 0.05). In one study among preterm group 
mean CORD BILIRUBIN was significant in males compared to female babies. 
In full term group mean CORD BILIRUBIN among male and female babies 
have no statistical significance. These results matched with Amar et al, Rostami 
and Mehrabi whereas it did not match with Ruby et al. 
  In this study the mean gestational age is 36.5 ± 1 and found this variable 
did not differ significantly. Mathias et al found that mean CORD BILIRUBIN 
is negatively correlated with gestational age. 
In this study the mean birth weight is 26 ± 0.1 was found that this 
variable did not differ significantly (P value more than 0.05). 
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Adelia et al and Canceicao et al found that there was no significant 
correlation between total CORD BILIRUBIN and birth weight (≥ 3.5 kg). 
Preterm and low birth weight newborns are more likely to develop jaundice as 
the liver is immature with low UDPGT with decreased liver excretion. 
In this study mode of delivery was 40% LABOUR NATURAL and 60% 
was CAESAREAN SECTION. Test of significance state that P more than 0.05 
i.e., there was no statistical significance between CORD BILIRUBIN and mode 
of delivery. These results matched with Amar, Rostami and Mehrabi et al. 
In this study ABO incompatibility requiring PHOTOTHERAPY  is 
present in 30% and non ABO constitutes 69.3% showed that there was no 
statistically significant association between ABO incompatibility and 
PHOTOTHERAPY  (P more than 0.05). In one study mean CORD BILIRUBIN 
for newborns who had PHOTOTHERAPY was 2.19 ± 0.24 mg/dL which is 
highly significant than those who didn’t receive it (1.49 ± 0.34 mg/dL). This 
study matched with Adelia, Canceicao et al. 
In this study about 18% of newborns with Rh incompatibility underwent 
PHOTOTHERAPY whereas 82% of newborns without Rh incompatibility 
underwent PHOTOTHERAPY. P value less than 0.001 indicates that 
PHOTOTHERAPY is very strongly associated with Rh incompatibility. 
In this study the mean CORD BILIRUBIN was significantly higher 
among ABO +ve newborns compared to ABO -ve ones. The mean CORD 
BILIRUBIN is found to be greater in Rh than in ABO incompatible groups. 
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These results didn’t agree with Adelia and Canceicao which showed that there 
is no significant difference in CORD BILIRUBIN between newborns with and 
without blood group incompatibility.  
In this study the mean age of mother and newborn with no 
hyperbilirubinemia is 25.9 ± 2.1 years, whereas on the other hand with 
hyperbilirubinemia is 27.2 ± 4.1 years. The difference between the above mean 
was statistically significant with P less than 0.05. 
In this study the mother with blood groups A-ve, B-ve, O-ve, O+ve were 
associated with HYPERBILIRUBINEMIA and A+ve, B+ve were not 
statistically associated with HYPERBILIRUBINEMIA ( P value less than 
0.001).  Neonatal blood groups were not statistically significantly associated 
with HYPERBILIRUBINEMIA and NHYPERBILIRUBINEMIA. 
In this study mean Hb of NONHYPERBILIRUBINEMIA was 14.2 ± 2.1 
gm/dL and HYPERBILIRUBINEMIA was 15.6 ± 0.7 gm/dL. The difference 
between them showed a very high statistical significance. 
In this study mean CORD BILIRUBIN between newborns with 
NONHYPERBILIRUBINEMIA and HYPERBILIRUBINEMIA were 2.3 ± 0.3 
and 4.0 ± 0.5 respectively. The difference them proved statistical significance ( 
P value less than 0.001). 
 In this study the relation between total CORD BILIRUBIN and SBR 
were statistically high significant. Logistic regression was applied only for  
CORD BILIRUBIN with NONHYPERBILIRUBINEMIA and 
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HYPERBILIRUBINEMIA because all other variables like GA, Sex, 
incompatibility were not statistically significant. 
In this study CORD BILIRUBIN cut off point is calculated by ROC 
curve. The diagonal segment of this curve gives the predictive value of CORD 
BILIRUBIN as 3.25 mg/dL. At this point sensitivity and specificity were 96% 
with youden index being 0.959 (Highest). 
Rudy et al determined this value using ROC as 2.54 mg/dL having high 
sensitivity and specificity. Amar et al's value was more than 2 mg/dL which had 
highest specificity and this critical bilirubin level had a very high NPV and 
fairly low PPV. Rostami and Mehrabi's value more than 3 mg/dL states that it 
was not a useful predictor for jaundice. Rataj et al showed that critical level in 
CORD BILIRUBIN ≥ 2.5 mg/dL had probability of 89% for the development 
of significant jaundice in new borns. 
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SUMMARY 
This study was conducted to find out the predictive (Cut off) value of 
umbilical cord bilirubin in identifying neonatal hyperbilirubinemia in healthy 
term newborns. This study was carried out on 150 newborns in Tirunelveli 
Medical College Hospital. Babies were chosen based on inclusion and 
exclusion criteria. This study group was followed up clinically and with 
laboratory parameters - CORD BILIRUBIN was measured at birth followed up 
using TCB  to find newborns developing jaundice in 1st week of life. Based on 
this the treatment modalities has been planned. 
RESULTS OF STUDY: 
Female babies were found to be higher i.e.,62.7% when compared to 
male babies 37.3%.  Mean gestational age being 36.5± 0.1. Mean birth weight 
being 2.6 ± 0.1. There was no statistically significant association exist between 
CORD BILIRUBIN and mode of delivery. There was no statistically significant 
association exist between ABO incompatibility and PHOTOTHERAPY. Rh 
incompatibility is statistically significantly associated with PHOTOTHERAPY. 
Mean total CORD BILIRUBIN is more in Rh incompatibility (4.23) when 
compared to ABO incompatibility (3.86). Mean difference between age of 
mother with HYPERBILIRUBINEMIA and NONHYPERBILIRUBINEMIA is 
statistically significant. Mothers blood group has statistical signification with 
HYPERBILIRUBINEMIA and NONHYPERBILIRUBINEMIA but it was not 
seen in babies blood group. The mean Hb of HYPERBILIRUBINEMIA and 
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NONHYPERBILIRUBINEMIA is 15.6 ± 0.7 and 14.2 ± 2 gm/dL respectively 
and difference between them was statistically significant. The mean CORD 
BILIRUBIN between babies with HYPERBILIRUBINEMIA and 
NONHYPERBILIRUBINEMIA was 4 ± 0.5 and 2.3 ± 0.3 mg/dL respectively 
and difference between them was statistically significant. The relationship 
between total CORD BILIRUBIN and SBR was statistically significant 
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CONCLUSION 
Study concludes that the total CORD BILIRUBIN in healthy term 
newborns provides prediction for neonatal jaundice in 1st week of life. The cut 
off value being 3.25 with 96.0% of specificity and 96.0% sensitivity. It is also 
evident that the presence of incompatibility in newborns (ABO, Rh) was 
statistically significant for occurrence of high total CORD BILIRUBIN that 
indicates PHOTOTHERAPY treatment. 
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PROFOMA 
BABY DETAILS  
Name   :  
Age   :  
Sex   :  
Date of Birth  :  
Gestational age : (Term / Preterm)  
Apgar   : 1 min  5 min  
MOTHER DETAILS  
Age   :  
LMP   :  EDD :   
Blood group  :  
Anti-D given / Not :  
History of drug in take / Jaundice / Blood transfusion / Fever with Rash:  
Family history of Jaundice / Gallstones:  
Thyroid disorder :  
Pervious Sibling with Jaundice:  
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RISK FACTORS  
Asphyxia / Sepsis / incompatibility / Hypoglycaemia / Hypothermia  
HISTORY  
Day of onset of Jaundice  
High coloured urine / Pale stools  
Birth Trauma  
EXAMINATION  
Clinical level of Jaundice (Kramer's rule)/ TCB  
Head to foot examination  
Cephalohematoma / Subgaleal bleed / Bruises  
Wide open AF/ PF  
Cataract / Chorioretinits / Cherry red spot  
features s/o Down's Syndrome  
Umbilical sepsis  
Petechie / Blue berry muffin spots  
Hepatosplenomegaly  
Cardiac Murmur presence 
INVESTIGATION  
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Cord Blood bilirubin  
Baby blood group / Mother blood group  
Serum bilirubin (Total / Indirect / Direct) 
Haemoglobin levels  
Day of Jaundice  
TREATMENT  
Phototherapy  
Day started  
Day Stopped  
Exchange transfusion  
Discharge  
  
86 
 
BIBILIOGRAPHY 
1. American Academy of Paediatrics, Subcommittee on Neonatal 
Hyperbilirubinemia. Neonatal jaundice and kernicterus. Paediatrics. 
2001;108:763–5. 
2. American Academy of Paediatrics, Jaundice section of Infant nutrition 
and development of gastrointestinal function. In RE Kleinman, ed., 
Paediatric Nutrition Handbook, 6th ed., 2009; 47-49. 
3. Kamath BD,  Jaundice. In SL Gardner et al., eds., Merenstein and 
Gardner's Handbook of Neonatal Intensive Care, 7th ed., 2011; 531–552. 
4. Sarci S U, Serdar MA, Korkmaz A, et al. Incidence, course and 
prediction of hyperbilirubinemia in near term and term newborns. 
Paediatrics.2004;113: 775–780. 
5. Kawade N, Onishi S. The perinatal and postnatal development of UDP- 
glucuronyl transferase activity towards bilirubin and the effect of 
premature birth on its activity in human liver. Biochem J. 1981;196:  
257–260. 
6. Bhutani VK, Johnson LH, Maisels MJ et al. Kernicterus; 
epidemiological strategies for its prevention through system based 
approach. J Perinatol.2004; 24: 650–662. 
7. Newman TB, Escobar GJ, Gonzales VM, Armstrong MA, et al . 
Frequency of neonatal bilirubin testing and hyperbilirubinemia in a large 
health maintenance organisation. Paediatrics 1999; 101: 995–998. 
87 
 
8. Maisels MJ, Kring E. Length of stay, jaundice and hospital readmission. 
PediatriCaesarean Section.1998; 101:995–998. 
9. Maisela MJ, Newman TB. Jaundice in full term and near term babies 
who leave the hospital within 36 hours: the paediatrician's nemesis. Clin 
Perinatol.1998: 25: 295–302 
10.  Geiger AM, Petitti DB, Yao JF Rehospitalisation for neonatal jaundice. 
Risk factors and outcomes. Paediatric Perinat Epidemiol.2001: 15: 352–
358. 
11.  Newman TB, Liljestrand P, Escoar GJ. Infants with bilirubin levels of 
30 mg/dl or more in a large managed care organisation. Paediatrics. 
2003; 111; 1303–1311. 
12.  Chou SC, Palmer RH, Ezhuthachan S et al. Management of 
hyperbiliubinemia in newborns: measuring performance by using a 
bench making model. Paediatrics. 2003: 112: 1264–1273. 
13.  Lee HC, Madan A , Hematologic abnormalities and jaundice. In CD 
Rudolph et al., eds., Rudolph's PediatriCaesarean Section, 22nd ed., 
2011; 226–233. 
14.  Behrman RE, Kliegman RM, Jenson HB, eds. Jaundice and 
hyperbilirubinemia in the newborn. Nelson Textbook of Paediatrics. 16th 
ed. Philadelphia: Saunders, 2000;511–28. 
15. Melton K, Akinbi HT, Neonatal jaundice. Strategies to reduce bilirubin-
induced complications. 1999;106:167–8,171–4,177–8. 
88 
 
16.  Maisels MJ, Newman TB, Kernicterus in otherwise healthy, breast-fed 
term newborns. Paediatrics. 1995;964  1:730–3. 
17.  Newman TB, Maisels MJ, Evaluation and treatment of jaundice in the 
term newborn: a kinder, gentler approach. PediatriCaesarean Section. 
1992;895 1:809–18. 
18.   Knudsen A, Ebbesen F, Cephalocaudal progression of jaundice in 
newborns admitted to neonatal intensive care units. Biol Neonate. 
1997;71:357–61. 
19.   Moyer VA, Ahn C, Sneed S, Accuracy of clinical judgment in neonatal 
jaundice. Arch Paediatric Adolesc Med. 2000;154:391–4. 
20.  Gartner LM, Herrarias CT, Sebring RH. Practice patterns in neonatal 
hyperbilirubinemia. Paediatrics. 1998;1011 Phototherapy  1:25–31. 
21.  Bhutani VK, Johnson L, Sivieri EM, Predictive ability of a pre 
discharge hour-specific serum bilirubin for subsequent significant 
hyperbilirubinemia in healthy term and near-term newborns. Paediatrics'. 
1999;103:6–14. 
22. Yetman RJ, Parks DK, Huseby V, Mistry K, Garcia J. Rebound bilirubin 
levels in infants receiving phototherapy. J Pediatr. 1998;133:705–7. 
23.  Jackson JC. Adverse events associated with exchange transfusion in 
healthy and ill newborns. Paediatrics. 1997;99:E7. 
24.  Brown AK, Kim MH, Wu YK, Bryla DA, Efficacy of phototherapy in 
prevention and management of neonatal hyperbilirubinemia. Paediatrics'. 
1985;752 Phototherapy  2:393–400. 
89 
 
25.  Manning D, Todd P, Maxwell M, et al. Prospective surveillance study of 
severe hyperbilirubinaemia in the newborn in the UK and Ireland. Arch 
Dis Child Fetal Neonatal  2007;92:F342–F346. 
26.  Ebbesen F, Andersson C, Verder H, et al. Extreme hyperbilirubinaemia 
in term and near-term infants in Denmark. Acta Paediatrica. 2005;94:59–
64. 
27.  Smitherman H, Stark AR, Bhutani VK, Early recognition of neonatal 
hyperbilirubinemia and its emergent management. Semin Fetal Neonatal 
Med. 2006;11:214–224. 
28.  Maisels MJ, Physiologic and pathologic jaundice: the conundrum of 
defining normal bilirubin levels in the newborn. Paediatrics. 
2006;118:805–807. 
29.  Wu PY, Hodgman JE, Kirkpatrick BV, et al. Metabolic aspects of 
phototherapy. Paediatrics. 1985;75:427–433. 
30.  Maisels MJ, Gifford K, Normal serum bilirubin levels in the newborn 
and the effect of breast-feeding. PediatriCaesarean Section. 
1986;78:837–843. 
31.  US Preventive Services, Agency for Healthcare Research and Quality. 
Screening of infants for hyperbilirubinemia to prevent chronic bilirubin 
encephalopathy: US Preventive Services Task Force recommendation 
statement. Paediatrics'. 2009;124:1172–1177. 
90 
 
32.  Trikalinos TA, Chung M, Lau J, et al. Systematic review of screening 
for bilirubin encephalopathy in neonates. PediatriCaesarean Section. 
2009;124:1162–1171. 
33.  Ip S, Chung M, Trikalinos T, et al. Screening for bilirubin 
encephalopathy. Agency for Healthcare Research and Quality. 2009;1. 
34.  Mishra S, Chawla D, Agarwal R, et al. Transcutaneous bilirubinometry 
reduces the need for blood sampling in neonates with visible jaundice. 
Acta Paediatr. 2009;98:1916–1919. 
35.  Dijk PH, Hulzebos CV. An evidence-based view on 
hyperbilirubinaemia. Acta Paediatr Suppl. 2012;101:3–10. 
36.  Thayyil S, Milligan DW. Single versus double volume exchange 
transfusion in jaundiced newborn infants. Cochrane Database Syst Rev. 
2006;(4):CD004592. 
37.  Reddy P, Najundaswamy S, Mehta R, et al. Tin-mesoporphyrin in the 
treatment of severe hyperbilirubinemia in a very-low-birth-weight infant. 
J Perinatol. 2003;23:507–508. 
38.  Murphy, J F; Hughes I; Verrier Jones ER; Gaskell S; Pike AW (1981). 
Pregnanediols and breast-milk jaundice.1981; 56: 474–76. 
39.  Nadir S, Saleem F, Amin K, Mahmood K (2011). Rational use of 
phototherapy in the treatment of physiologic jaundice neonatorum 
(PDF). Journal of Pharmaceutical Sciences and Research (Journal of 
Pharmaceutical Sciences and Research) 3 (1). 
91 
 
40. Dobbs, R H; R J Cremer , Phototherapy. Archives of Disease in 
Childhood 1975; 833–836. 
41.  Stokowski LA, Fundamentals of phototherapy for neonatal jaundice. 
Adv Neonatal Care (6)2006; 303–12. 
42. Colletti, JE; Kothari, S; Kothori, S; Jackson, DM; Kilgore, KP; 
Barringer, K, An emergency medicine approach to neonatal 
hyperbilirubinemia. Emerg. Med. Clin. North Am. 25 (4):2007;1117–35. 
43.  American Academy of Paediatrics. AAP Issues New Guidelines for 
Identifying and Managing Newborn Jaundice. Retrieved 4 July 2009. 
44.  Kiviahan C, Jams EJ, The natural history of neonatal jaundice, 
PediatriCaesarean Section, 1984; 74, 364–370. 
45.  Martin CR, Cloherty JP. Neonatal hyperbilirubinemia, In Manual of 
Neonatal Care. In Cloherty JP, Eichenwald EC, Stark AR. 5th edition, 
Philadelphia, Lippincott Williams & Wilkins 2004; 185–221. 
46.  Kramer LI, Advancement of dermal icterus in jaundiced newborn. Am J 
Dis Child 1969; 118,454–8. 
47.  Maisels MJ, Baltz RD, Bhutani V, et al. Management of 
hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. 
Paediatrics 2004;114,297–316. 
48.  Maisels MJ, Jaundice, In Avery's Neonatology Pathophysiology & 
Management of the Newborn. Eds: MacDonald MG, Mullett MD, Seshia 
MMK, 6th editon; Lippincott Williams & Wilkins, Philadelphia, 2005; 
775. 
92 
 
49.  Abu-Ekteish, F, Daoud, A, Rimawi, H, Kakish, K, & Abu-Heija, A, 
Neonatal exchange transfusion: Ajordanian experience. Annals of 
Tropical Paediatrics,2000; 20(1), 57–60. 
50.  Agarwal, R Kaushal, M Aggarwal, R Paul, V. K., & Deorari, A. K. 
Early neonatal hyperbilirubinemia using first day serum bilirubin level. 
Indian Paediatrics,2002; 39(8), 724–730. 
51.  Ahlfors, C. E. Unbound bilirubin associated with kernicterus: A 
historical approach. Journal of PediatriCaesarean Section,2000;137(4), 
540–544. 
52.  AlOtaibi, S. F., Blaser, S., & MacGregor, D. L. Neurological 
complications of kernicterus. Canadian Journal of Neurological 
Sciences, 2005;32(3), 311–315. 
53.  Alpay, F., Sarici, S. U., Tosuncuk, H. D., Serdar, M. A., Inanc, N., & 
Gokcay, E. The value of first-day bilirubin measurement in predicting 
the development of significant hyperbilirubinemia in healthy term 
newborns. PediatriCaesarean Section,2000; 106(2), E16. 
54.  Basu, K Das, P. K Bhattacharya, R & Bhowmik, P. K. A new look on 
neonatal jaundice. Journal of the Indian Medical Association,2002; 
100(9), 556–560. 
55.  Bental, Y. A Shiff, Y Dorsht, N Litig, E Tuval, L & Mimouni, F. B. 
Bhutani-based nomograms for the prediction of significant 
hyperbilirubinaemia using transcutaneous measurements of bilirubin. 
Acta Paediatrica,2009; 98(12), 1902–1908. 
93 
 
56.  Bhat, Y. R & Rao, A. Transcutaneous bilirubin in predicting 
hyperbilirubinemia in term neonates. Indian Journal of PediatriCaesarean 
Section,2008; 75(2), 119–123. 
57.  Bhutani, V. K Gourley, G. R Adler, S Kreamer, B Dalin, C & Johnson, 
L. H. Noninvasive measurement of total serum bilirubin in a multiracial 
predischarge newborn population to assess the risk of severe 
hyperbilirubinemia. PediatriCaesarean Section,2000; 106(2), E17. 
58.  Carbonell, X Botet, F Figueras, J & Riu-Godo, A. Prediction of 
hyperbilirubinemia in the healthy term newborn. Acta Paediatrica, 
2001;90(2), 166–170. 
59.  Centres for Disease Control and Prevention (CDC), Kernicterus in full-
term infants--united states, 1994-1998. MMWR - Morbidity & Mortality 
Weekly Report,2001; 50(23), 491–494. 
60.  Funato, M Tamai, H Shimada, S & Nakamura, H. Vigintiphobia, 
unbound bilirubin, and auditory brainstem responses. PediatriCaesarean 
Section,1994; 93(1), 50–53. 
61.  Hansen TW. Mechanisms of bilirubin toxicity: Clinical implications. 
Clin Perinatol 2002;29:765–778. 
62.  Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the 
term newborn: A kinder, gentler approach. Paediatrics 1992;809–18.  
63.  Penn AA, Enzmann DR, Hahn JS, Stevenson DF. Kernicterus in a full 
term infant. Paediatrics 1994;1003–6. 
94 
 
64.  Stevenson DK, Fanaroff AA, Maisels MJ, et al. Prediction of 
hyperbilirubinemia in near-term and term infants. Paediatrics 
2001;108:31–9. 
65.  Johnson LH, Bhutani VK, Brown AK. System-based approach to 
management of neonatal jaundice and prevention of kernicterus. J 
Pediatr 2002;140:396–403. 
66.  Centres for Disease Control and Prevention (CDC). Kernicterus in full 
term infants – United States, 1994-1998; MMWR Morb Mortal Wkly 
Rep 2001;50:491–4. 
67.  Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. 
N Engl J Med 2001;344:581–90. 
68.  Seidman DS, Ergaz Z, Paz I, et al. Predicting the risk of jaundice in full-
term healthy newborns: A prospective population-based study. J 
Perinatol 1999;19(8 Phototherapy  1):564–7. 
69.  Sarici SU, Yurdakok M, Serdar MA, et al. An early (sixth-hour) serum 
bilirubin measurement is useful in predicting the development of 
significant hyperbilirubinemia and severe ABO hemolytic disease in a 
selective high-risk population of newborns with ABO incompatibility. 
PediatriCaesarean Section 2002;109:e53. 
70.  Carbonell X, Botet F, Figueras J, Riu-Godo A. Prediction of 
hyperbilirubinaemia in the healthy term newborn. Acta Paediatr 
2001;90:166–70. 
95 
 
71.  Madlon-Kay DJ. The clinical significance of ABO blood group 
incompatibility. Arch Fam Med 1993;2:285–7. 
72.  Rubaltelli FF, Gourley GR, Loskamp N, et al. Transcutaneous bilirubin 
measurement: A multicentre evaluation of a new device. 
PediatriCaesarean Section 2001;107:1264–71. 
73.  Brown AK, Kim MH, Wu PY, Bryla DA. Efficacy of phototherapy in 
prevention and management of neonatal hyperbilirubinemia. 
PediatriCaesarean Section 1985;75(2 Phototherapy  2):393-400. 
 
1 Min 5Min
1 B/O Saraswathy 03-03-2015 36 MCH 30 2.5 7/10 8/10 AGA 1
2 B/O Ganasundari 03-03-2015 36 MCH 30 2.8 8/10 9/10 AGA 1
3 B/O Petchiammal 03-03-2015 36 MCH 28 2.6 8/10 9/10 AGA 1
4 B/O Jasmine 03-03-2015 37 FCH 28 2.7 7/10 8/10 AGA 1
5 B/O Aysha Beevi 04-03-2015 37 MCH 32 2.9 7/10 8/10 AGA 1
6 B/O Selidipinol 04-03-2015 36 MCH 26 2.1 7/10 8/10 LBW 2
7 B/O Muthu Selvi 04-03-2015 37 MCH 30 2.6 7/10 8/10 AGA 2
8 B/O Selvaklakshmi 04-03-2015 36 MCH 28 2.3 8/10 9/10 LBW 1
9 B/O Muthu Selvi 04-03-2015 36 FCH 28 3 8/10 9/10 AGA 1
10 B/O Syed Ali Fathima 04-03-2015 37 FCH 31 2.5 7/10 8/10 AGA 1
11 B/O Victoria 04-03-2015 36 MCH 29 2.9 8/10 9/10 AGA 2
12 B/O Mariselvi 04-03-2015 36 MCH 26 2.5 8/10 9/10 AGA 2
13 B/O Thaiammal 04-03-2015 36 MCH 28 2.5 8/10 9/10 AGA 1
14 B/O Asanbath 04-03-2015 37 FCH 30 2.3 7/10 8/10 LBW 1
15 B/O ArunaDevi 06-03-2015 37 MCH 28 2.8 7/10 8/10 AGA 1
16 B/O Nerosha 06-03-2015 36 FCH 25 2.7 7/10 8/10 AGA 1
17 B/O Mupidathy 06-03-2015 37 MCH 28 2 7/10 8/10 LBW 1
18 B/O Lakshmi 06-03-2015 36 MCH 22 2.5 7/10 8/10 AGA 1
19 B/O Petchiammal 06-03-2015 36 MCH 26 2.8 7/10 8/10 AGA 2
20 B/O Gomathiammal 06-03-2015 36 MCH 30 2.9 7/10 8/10 AGA 2
21 B/O Kuparal 06-03-2015 37 FCH 25 2.2 7/10 8/10 LBW 1
22 B/O Murugaeswari 06-03-2015 37 FCH 26 3.1 7/10 8/10 AGA 1
23 B/O Malarvili 07-03-2015 37 FCH 29 2.8 7/10 8/10 AGA 2
24 B/O Savithiri 07-03-2015 37 MCH 22 3.2 7/10 8/10 AGA 2
25 B/O Sasikala 07-03-2015 37 MCH 22 2.8 7/10 8/10 AGA 1
26 B/O Natchiaa 07-03-2015 36 MCH 29 2.9 7/10 8/10 AGA 1
27 B/O Uma Maheshwari 07-03-2015 37 MCH 22 2.2 7/10 8/10 LBW 2
28 B/O Tharani 07-03-2015 37 MCH 26 3 7/10 8/10 AGA 1
29 B/O Lakshmi 07-03-2015 37 MCH 26 2.9 7/10 8/10 AGA 1
30 B/O Kavitha 07-03-2015 36 FCH 20 2.8 7/10 8/10 AGA 3
31 B/O Ishaki Thai 07-03-2015 36 FCH 20 2.2 7/10 8/10 LBW 3
32 B/O Muthulakshmi 07-03-2015 36 FCH 22 2.6 8/10 9/10 AGA 3
33 B/O Karpagavalli 07-03-2015 36 FCH
25
2.8 7/10 8/10 AGA 3
34 B/O Ganamathi 07-03-2015 36 FCH 24 2.6 7/10 8/10 AGA 1
35 B/O Buvaneswari 07-03-2015 37 FCH 20 2.3 7/10 8/10 LBW 3
36 B/O Sathya 07-03-2015 36 FCH 27 2.8 7/10 8/10 AGA 3
37 B/O Subammal 07-03-2015 36 FCH 23 2.7 7/10 8/10 AGA 2
38 B/O Maragathavalli 09-03-2015 37 FCH 22 2.1 7/10 8/10 LBW 3
39 B/O Lakshmi 09-03-2015 36 FCH
24
2.8 7/10 8/10 AGA 1
40 B/O Poomari 09-03-2015 37 MCH 22 2.6 8/10 9/10 AGA 1
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41 B/O Subulakshmi 09-03-2015 36 MCH 26 2.9 7/10 8/10 AGA 1
42 B/O Rohini 09-03-2015 37 MCH 30 2.8 7/10 8/10 AGA 1
43 B/O Poornima 09-03-2015 36 FCH 32 3.1 7/10 8/10 AGA 2
44 B/O Banumathi 09-03-2015 36 FCH 29 2.2 7/10 8/10 AGA 1
45 B/O Anita 10-03-2015 36 MCH 26 2.5 7/10 8/10 AGA 1
46 B/O Lakshmi 11-03-2015 36 FCH 35 2.6 7/10 8/10 AGA 1
47 B/O Muthu Lakshmi 11-03-2015 36 FCH 30 2.6 7/10 8/10 AGA 1
48 B/O Kanagumari 11-03-2015 36 FCH 29 2.2 7/10 8/10 LBW 1
49 B/O Maha Lakshmi 11-03-2015 36 FCH 29 2.6 7/10 8/10 AGA 1
50 B/O Gandhimathi 11-03-2015 37 FCH 26 2.4 7/10 8/10 LBW 2
51 B/O Ramalakshmi 11-03-2015 37 FCH 25 2.8 7/10 8/10 AGA 1
52 B/O Sudha 11-03-2015 37 FCH 28 2.2 7/10 8/10 LBW 1
53 B/O Kavitha 12-03-2015 37 FCH 32 3 7/10 8/10 AGA 2
54 B/O Maheswari 13-03-2015 37 FCH 28 2.1 7/10 8/10 LBW 3
55 B/O Shankari 13-03-2015 37 FCH 24 2.8 7/10 8/10 AGA 2
56 B/O Uthami 13-03-2015 37 FCH 25 2.5 7/10 8/10 AGA 3
57 B/O Amutha 14-03-2015 36 MCH
30
2.8 7/10 8/10 AGA 1
58 B/O Murugeswari 14-03-2015 37 FCH 28 2.2 7/10 8/10 LBW 2
59 B/O Vanitha 14-03-2015 37 FCH 26 2.9 7/10 8/10 AGA 1
60 B/O Subalakshmi 14-03-2015 37 FCH 22 2.6 7/10 8/10 AGA 2
61 B/O Kalaiselvi 14-03-2015 37 FCH 23 2.2 7/10 8/10 LBW 1
62 B/O Rajalakshmi 14-03-2015 36 FCH 26 2.8 7/10 8/10 AGA 2
63 B/O Ramayi 14-03-2015 36 FCH 28 2.6 7/10 8/10 AGA 1
64 B/O Manoramma 14-03-2015 36 FCH 28 3 7/10 8/10 AGA 1
65 B/O Malathi 15-03-2015 36 FCH 24 2.3 7/10 8/10 LBW 2
66 B/O Mariammal 15-03-2015 36 FCH 30 2.6 7/10 8/10 AGA 1
67 B/O Valavanthal 15-03-2015 37 FCH 30 2.1 7/10 8/10 LBW 2
68 B/O Roilala 16-03-2015 37 FCH 32 3 7/10 8/10 AGA 2
69 B/O Ishaki Ammal 16-03-2015 37 FCH 30 2.9 7/10 8/10 AGA 1
70 B/O Manoharamma 16-03-2015 36 FCH 29 2.8 7/10 8/10 AGA 1
71 B/O Lakshmi 16-03-2015 36 FCH 25 2.1 7/10 8/10 LBW 2
72 B/O Ajmal 16-03-2015 37 FCH 22 2.8 7/10 8/10 AGA 1
73 B/O Hyarnisha 16-03-2015 37 FCH 26 2.5 7/10 8/10 AGA 1
74 B/O Lakshmi 16-03-2015 36 MCH 20 3 7/10 8/10 AGA 1
75 B/O Uma Maheshwari 17-03-2015 37 FCH 29 2.3 7/10 8/10 LBW 1
76 B/O Pappa 17-03-2015 37 MCH 30 2.7 7/10 8/10 AGA 2
77 B/O Mumtaj Banu 17-03-2015 36 MCH 25 2.6 7/10 8/10 AGA 1
78 B/O Perumal 18-03-2015 37 FCH 28 2.7 7/10 8/10 AGA 2
79 B/O Rukmani 18-03-2015 36 MCH 25 2.2 8/10 9/10 LBW 1
80 B/O Aabikar 18-03-2015 36 MCH 28 2.7 8/10 9/10 AGA 1
81 B/O Bagavathy 18-03-2015 37 MCH 26 3 7/10 8/10 AGA 1
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82 B/O Muthu Kalayani 19-03-2015 37 FCH 30 2.5 7/10 8/10 AGA 2
83 B/O Murugavalli 19-03-2015 36 FCH 26 2.8 7/10 8/10 AGA 1
84 B/O Shanthi 19-03-2015 37 MCH 35 2.5 7/10 8/10 AGA 2
85 B/O Shanthini 20-03-2015 37 FCH 28 2.1 7/10 8/10 LBW 1
86 B/O Maheswari 21-03-2015 37 FCH 25 2.8 7/10 8/10 AGA 2
87 B/O Murugaselvi 21-03-2015 37 FCH 26 2.9 7/10 8/10 AGA 1
88 B/O Nagammal 24-03-2015 36 MCH 30 3 7/10 8/10 AGA 1
89 B/O Arumugalakshmi 25-03-2015 36 FCH 26 2.6 8/10 9/10 AGA 2
90 B/O Amudha 25-03-2015 36 FCH 23 2 8/10 9/10 LBW 1
91 B/O Veyilatchi 25-03-2015 37 FCH 23 2.7 7/10 8/10 AGA 3
92 B/O Devi 25-03-2015 37 FCH 32 2.7 7/10 8/10 AGA 1
93 B/O Chellamari 25-03-2015 37 FCH 26 2.5 7/10 8/10 AGA 1
94 B/O Lakshmi 26-03-2015 36 MCH 31 2.6 7/10 8/10 AGA 2
95 B/O Punitha 27-03-2015 37 FCH 38 2.8 8/10 9/10 AGA 2
96 B/O Mariammal 27-03-2015 37 FCH 27 2.4 7/10 8/10 LBW 1
97 B/O Subha 27-03-2015 37 FCH 28 2.9 7/10 8/10 AGA 1
98 B/O Pirakasi 28-03-2015 37 FCH 27 2.9 7/10 8/10 AGA 1
99 B/O Thanthondri 28-03-2015 36 MCH 30 3 7/10 8/10 AGA 1
100 B/O Gomathi 28-03-2015 36 MCH 27 2.1 7/10 8/10 LBW 1
101 B/O Mariammal 28-03-2015 37 MCH 29 3.1 7/10 8/10 AGA 2
102 B/O Banumathy 28-03-2015 37 MCH 25 3 7/10 8/10 AGA 2
103 B/O Usha 28-03-2015 37 MCH 26 2.2 7/10 8/10 LBW 1
104 B/O Andal 28-03-2015 37 MCH 22 2.5 7/10 8/10 AGA 1
105 B/O Thalavaiselvi 30-03-2015 36 FCH 25 2.6 7/10 8/10 AGA 3
106 B/O Sundarammal 30-03-2015 37 FCH 26 2.6 8/10 9/10 AGA 1
107 B/O Muthukani 30-03-2015 37 FCH 25 2 8/10 9/10 LBW 1
108 B/O Maya 31-03-2015 37 FCH 21 3 7/10 8/10 AGA 2
109 B/O Ponnammal 01-04-2015 37 MCH 41 2.8 7/10 8/10 AGA 3
110 B/O Vasanthi 01-04-2015 36 MCH 25 2.6 7/10 8/10 AGA 1
111 B/O Uma Maheshwari 01-04-2015 37 FCH 24 2.7 7/10 8/10 AGA 2
112 B/O Indhra 01-04-2015 37 FCH 22 2.4 7/10 8/10 LBW 1
113 B/O Viswarohini 02-04-2015 36 MCH 24 2.5 8/10 9/10 AGA 1
114 B/O Vishnavi 02-04-2015 37 MCH 22 2.8 8/10 9/10 AGA 1
115 B/O Navanithan 02-04-2015 37 MCH 26 2.7 8/10 9/10 AGA 1
116 B/O Thavasimani 02-04-2015 37 FCH 28 2.7 8/10 9/10 AGA 1
117 B/O Subarani 02-04-2015 36 FCH 27 2.9 7/10 8/10 AGA 2
118 B/O Sankarammal 02-04-2015 36 FCH 22 2.2 7/10 8/10 LBW 1
119 B/O Gayathri 02-04-2015 36 FCH 25 2.6 7/10 8/10 AGA 1
120 B/O Malini 02-04-2015 37 FCH 24 2.8 7/10 8/10 AGA 2
121 B/O Murugalakshmi 03-04-2015 37 FCH 22 2.6 7/10 8/10 AGA 1
122 B/O Adhira 03-04-2015 37 FCH 26 2.8 7/10 8/10 AGA 1
123 B/O Esakiammal 07-04-2015 36 FCH 32 2.5 7/10 8/10 AGA 2
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124 B/O Princes Pani Mary 07-04-2015 36 MCH 29 2.3 7/10 8/10 LBW 2
125 B/O Sankarammal 07-04-2015 36 MCH 28 2.8 7/10 8/10 AGA 2
126 B/O Chella Mary 08-04-2015 37 FCH 29 2.7 8/10 9/10 AGA 1
127 B/O Kaliswari 12-04-2015 37 FCH 24 3 7/10 8/10 AGA 2
128 B/O Sudha 12-04-2015 37 FCH 26 2.6 7/10 8/10 AGA 1
129 B/O Nandini 22-04-2015 37 FCH 30 2.1 7/10 8/10 LBW 1
130 B/O Thamayanthi 22-04-2015 37 FCH 27 3 7/10 8/10 AGA 1
131 B/O Shanthi 29-04-2015 37 MCH 36 2.8 7/10 8/10 AGA 1
132 B/O Parameswari 02-05-2015 36 FCH 25 2.6 7/10 8/10 AGA 1
133 B/O Banu Priya 02-05-2015 36 FCH 27 2.4 7/10 8/10 LBW 1
134 B/O Muthulakshmi 02-05-2015 37 MCH 24 2.5 7/10 8/10 AGA 1
135 B/O Genetamary 03-05-2015 37 FCH 27 2.6 7/10 8/10 AGA 1
136 B/O Maharani 03-05-2015 37 FCH 23 2.9 7/10 8/10 AGA 1
137 B/O Thirumalai Selvi 06-05-2015 37 FCH 21 3 7/10 8/10 AGA 2
138 B/O Sankarammal 06-05-2015 36 FCH 31 2.5 7/10 8/10 AGA 1
139 B/O Saraswathy 06-05-2015 36 MCH 31 2.6 7/10 8/10 AGA 2
140 B/O Thangam 06-05-2015 36 MCH 26 2.2 7/10 8/10 LBW 1
141 B/O Shanmugasundhari 08-05-2015 37 FCH 30 2.7 7/10 8/10 AGA 1
142 B/O Kanmani 10-05-2015 37 FCH 28 2.9 7/10 8/10 AGA 1
143 B/O Mahalaxmi 10-05-2015 37 FCH 29 3 7/10 8/10 AGA 1
144 B/O Thanga Selvi 13-05-2015 36 FCH 32 2.9 7/10 8/10 AGA 1
145 B/O Siva Sankari 13-05-2015 37 MCH 23 3 8/10 9/10 AGA 1
146 B/O Mupidathy 13-05-2015 37 MCH 25 2.4 8/10 9/10 LBW 1
147 B/O Ganasevli 13-05-2015 37 MCH 23 2.6 8/10 9/10 AGA 1
148 B/O Mupidathy 13-05-2015 37 FCH 21 2.9 7/10 8/10 AGA 2
149 B/O Perutchi 19-05-2015 36 FCH 27 2.8 8/10 9/10 AGA 1
150 B/O KaniMaryal 19-05-2015 37 MCH 25 2.9 8/10 9/10 AGA 1
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Sl. 
No M
o
d
e 
o
f 
d
el
iv
er
y
Mother  Baby 1 2 3 4 5 6 7
LN AB+ B+ 16.1 Yes
CS PIH O+ A+ 15.8 Yes
CS A+ A+ 14.1
CS PIH A+ A+ 15.9 Yes
LN B- B+ 16.3 No Yes
LN O+ B+ 14.6
CS CPD IN O+ B+ 15.9 Yes
LN O+ B+ 17.1 Yes
LN O+ A+ 14.5
CS O+ A+ 14.5 Yes
LN O+ A+ 14.6 Yes
CS Previous LSCS A+ A+ 14.3
CS B+ B+ 14.7
LN O+ O+ 15.1 Yes
LN B+ AB+ 16.2 Yes
CS CPD IN B+ O+ 14.5
LN O+ B+ 15.8 Yes
LN B- B+ 15.9 No Yes
CS Previous LSCS A+ O+ 14.2
CS PIH O- B+ 14.5 Yes Yes
LN A- A- 15.2 Yes
LN A+ O+ 14.3
LN AB+ B+ 15.6 Yes
CS Previous LSCS O+ A+ 14.9 Yes
CS O+ A+ 16.1 Yes
LN AB+ O+ 14.7
CS Previous LSCS O+ B+ 15.7 Yes
CS O+ A+ 15.1 Yes
CS PIH O+ O+ 14.1
LN A- O+ 14.9 Yes Yes
LN O+ B+ 15.1 Yes
LN A+ A+ 14.8
CS
CPD IN 
LABOUR O+ A+ 14.5 Yes
CS O+ A+ 14.6
LN O+ A+ 16.1 Yes
LN O+ B+ 15.8 Yes
CS O+ A+ 14.4
LN B- B+ 15.9 No Yes
CS
PRIMI WITH 
CPD O+ A+ 15.6 Yes
CS O+ B+ 14.8 Yes
Blood Group                                                     
Hyperbilirubinemia                                                                                                                                          
DaysHb Level
Anti-D
Given
Indication for 
CS  
Sl. 
No
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
M
o
d
e 
o
f 
d
el
iv
er
y
Mother  Baby 1 2 3 4 5 6 7
Blood Group                                                     
Hyperbilirubinemia                                                                                                                                          
DaysHb Level
Anti-D
Given
Indication for 
CS  
CS O+ B+ 14.5
LN O+ O+ 14.6 Yes
LN B- B- 15.3 Yes
LN A+ B+ 14.7
LN B+ B+ 16.3 Yes
CS PIH O+ AB+ 16.1 Yes
CS PIH O+ A+ 16.6 Yes
CS B+ B+ 14.9
CS PIH O+ B+ 15.9 Yes
LN B- B+ 16.4 Yes
LN A+ A+ 14.1
LN O+ A+ 14.5 Yes
CS Previous LSCS A+ A+ 14.6 Yes
LN A- A- 14.6 Yes
LN B+ B+ 14.8
LN O+ A+ 14.8 Yes
CS
SHORT PRIMI 
WITH CPD B- B+ 16.2 Yes Yes
LN O- O+ 16.8 Yes
LN O+ O+ 14.2
LN O- B+ 16.1 Yes
LN A+ A+ 14.3
CS Previous LSCS O+ B+ 14.8 Yes
CS O+ B+ 14.5
LN O+ O+ 15.1 Yes
LN O- B+ 15.9 Yes
LN O+ O+ 14.6
CS Previous LSCS O+ O+ 14.8 Yes
LN B+ B+ 15.1 Yes
LN B- B+ 16.3 Yes
LN B+ B+ 14.3
CS O- O+ 16.4 Yes Yes
LN B- B+ 16.5 Yes
LN A+ A+ 14.8
CS CPD O- O- 14.8 Yes
LN B+ AB+ 14.6 Yes
LN O- A+ 15.9 Yes Yes
LN B+ B+ 14..4
LN A- A+ 15.5 Yes Yes
CS PIH O- O+ 15.6 Yes
CS PIH O- B- 14.3
LN O+ B+ 14.7 Yes
Sl. 
No
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
M
o
d
e 
o
f 
d
el
iv
er
y
Mother  Baby 1 2 3 4 5 6 7
Blood Group                                                     
Hyperbilirubinemia                                                                                                                                          
DaysHb Level
Anti-D
Given
Indication for 
CS  
LN B- B+ 16.7 Yes Yes
LN O+ A+ 14.6
LN A- A+ 16.1 Yes Yes
CS PIH O- B+ 15.9 Yes
LN AB+ AB+ 14.9 Yes
LN A- A- 14.9
LN AB+ A+ 15.1 Yes
LN O- A+ 17.3 Yes Yes
LN A+ A+ 14.7
LN B+ AB+ 14.8 Yes
LN B- B- 15.4 Yes
LN B+ O+ 14.3
CS CPD O+ O+ 15.3 Yes
LN B+ B+ 14.9 Yes
LN O+ B+ 15.1 Yes
LN AB+ B+ 14.7
CS CPD O+ A+ 16.4 Yes
LN O+ B+ 15.1 Yes
LN B+ B+ 14.6
LN O+ B+ 14.9 Yes
CS Previous LSCS O+ A+ 14.5 Yes
CS B+ B+ 14.2
CS AB+ A+ 14.3
LN B+ B+ 15.2 Yes
LN B+ A+ 15.1 Yes
LN A+ A+ 14.5
CS Previous LSCS O+ B+ 16.2 Yes
LN O- A+ 16.8 Yes Yes
LN A+ B+ 14.8
CS CPD AB+ AB+ 15.2 Yes
CS B+ A+ 14.1
LN O+ B+ 14.9 Yes
LN O+ O+ 14.5
LN A+ O+ 14.3
CS O+ A+ 15.7 Yes
LN B+ B+ 14.6 Yes
CS PIH AB+ AB+ 14.9 Yes
CS O+ B+ 14.8
CS CPD O+ O+ 16.1 Yes
LN B+ B+ 15.2 Yes
LN AB+ B+ 14.2
LN AB+ B+ 16.3 Yes
Sl. 
No
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
M
o
d
e 
o
f 
d
el
iv
er
y
Mother  Baby 1 2 3 4 5 6 7
Blood Group                                                     
Hyperbilirubinemia                                                                                                                                          
DaysHb Level
Anti-D
Given
Indication for 
CS  
CS Previous LSCS B+ B+ 15.3 Yes
CS A+ A+ 14.6
LN O+ O+ 15.6 Yes
CS PIH O- B+ 16.9 Yes Yes
CS A+ O+ 14.3
LN O+ B+ 14.9 Yes
LN O+ B+ 14.8
LN A- A+ 16.2 Yes
CS CPD O+ B+ 14.9 Yes
CS O- O- 14.2
LN O+ A+ 15.7 Yes
LN B+ B+ 15.2 Yes
LN O+ B+ 14.7
CS Previous LSCS AB+ B+ 15.8 Yes
LN B+ B+ 15.9 Yes
LN B- B+ 17.5 Yes
LN A+ A+ 14.8
CS CPD A- B+ 14.9 Yes
LN A- A+ 15.7 Yes
LN B+ B+ 14.3
LN A- A+ 16.8 Yes
CS PIH O- O+ 15.5 Yes
CS A+ A+ 14.1
CS B+ B+ 14.5
CS Previous LSCS B+ B+ 16.1 Yes
CS CPD A+ O+ 15.1 Yes
LN PIH B+ O+ 14.9 Yes
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Sl. 
No
1 2 3 4 5 6 7
4.6/3.6 6.9/5.8 11.1/10.6
4.6/4.0 8.2/7.6
2.2/1.1 2.6/2.1
3.7/3.4 7.1/6.3 11.5/10.6
4.4/3.4 12.8/11.9
2.4/2.0 2.9/2.6
4.1/4.0 7.2/6.5 12.0/11.5
5.3/4.3 9.5/8.8
2.3/2.0 2.7/2.5
3.2/2.4 7.4/6.8 12.5/11.7
3.6/3.2 7.4/6.7 12.2/11.4
2.3/1.6 2.5/1.9
2.0/1.6 2.2/1.8
3.9/3.1 6.5/5.8 10.2/9.5 13.6/12.8
4.5/3.4 6.8/6.1 12.1/11.2
2.5/2.0 2.7/2.2
4.2/3.6 6.5/5.8 11.5/10.7
4.2/3.1 12.5/11.9
2/1.5 2.3/1.9
3.8/2.1 6.9/6.1 12.2/11.4
4.2/3.4 7.4/6.6 13.3/12.6
2.0/1.4 2.3/1.8
4.8/3.9 6.8/6.1 12.2/11.4
3.6/2.6 7.0/6.3 10.1/9.6 13.5/12.7
4.3/3.2 7.3/6.5 10.4/9.7 13.8/12.9
2.5/2.0 2.7/2.0
4.0/3.2 10.6/9.8
3.9/3.1 11.2/10.8
2.3/1.7 2.5/1.9
3.2/2.7 7.2/6.6 10.8/9.9 13.8/12.9
3.2/2.4 11.2/10.4
2.4/1.9 2.5/2.0
3.5/2.6 6.9/6.1 12.6/11.8
2.0/1.4 2.3/1.6
4.3/3.4 7.2/6.8 13.8/13.4
3.7/3.4 6.9/5.9 12.4/11.6
2.5/1.8 2.6/2.0
4.6/4.1 13.2/12.7
4.3/3.5 10.5/9.7
3.2/2.4 7.1/6.3 12.2/11.4
  SBR      T/ID                                                                                                  
Days 
CBR 
T/ID
Sl. 
No
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
1 2 3 4 5 6 7
  SBR      T/ID                                                                                                  
Days 
CBR 
T/ID
2.1/1.8 2.3/1.9
3.6/2.2 6.8/6.1 10.4/9.6 13.0/12.3
4.2/3.6 6.5/5.8 11.9/10.9
2.3/1.9 2.5/2.0
4.3/3.4 6.9/6.1 11.8/10.9
4.1/3.6 7.1/6.6 10.5/9.6 12.6/11.8
4.4/3.6 10.8/9.9
2.6/2.1 2.9/2.0
4.1/3.4 7.2/6.4 12.6/11.8
4.4/3.6 13.3/12.5
3.1/2.6 4.8/3.9
3.3/2.9 7.3/6.5 10.8/9.9 13.6/12.8
3.5/2.8 6.9/5.9 11.6/10.9
3.5/2.6 7.3/6.4 10.2/9.4 13.1/12.8
2.0/1.2 2.3/1.9
3.5/2.9 7.2/6.5 12.1/11.3
4.4/3.7 12.1/11.2
5.4/4.8 15.2/14.2 12.8/12.1
2.6/1.8 2.9/1.3
4.2/3.3 14.5/13.7 12.7/11.8
2.3/1.9 2.5/2.0
3.3/2.7 6.8/6.1 11.8/10.9
2.0/1.4 2.3/1.7
3.6/2.7 7.1/6.5 12.1/11.7
4.6/3.7 13.1/12.3
2.3/1.9 2.4/2.0
3.9/3.1 7.2/6.6 12.6/11.8
3.6/3.1 7.4/6.5 10.6/9.8 13.6/12.8
4.6/3.9 13.9/13.1
2.4/1.8 2.6/2.0
4.2/3.6 14.1/13.6 12.2/11.5
4.3/3.6 13.9/13.3
2.9/2.4 3.0/2.5
3.6/2.8 7.1/6.3 10.2/9.4 12.3/11.5 14.2/13.4
3.7/3.1 6.9/6.1 13.1/12.4
4.3/3.6 14.5/13.7
2.2/1.8 2.5/2.0
4.2/3.6 11.5/10.7
4.3/3.9 11.8/10.9
2.3/2.0 2.5/1.9
3.6/2.9 7.1/6.4 12.5/13.7
Sl. 
No
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
1 2 3 4 5 6 7
  SBR      T/ID                                                                                                  
Days 
CBR 
T/ID
4.5/3.6 10.9/9.9
2.1/1.5 2.4/2.1
4.1/3.6 10.1/9.2
4.0/3.9 11.3/10.6
3.5/2.9 6.9/6.2 9.8/9.1 12.9/12.1
2.3/1.9 2.4/2.1
3.5/2.9 6.9/6.1 10.1/9.3 12.0/11.4
5.1/4.1 14.2/13.6 12.2/11.4
2.1/1.3 2.4/1.7
3.6/2.8 7.1/6.5 12.1/11.6
4.0/3.1 6.9/6.1 11.6/10.8
2.0/1.3 2.2/1.6
3.8/2.9 6.8/5.9 10.1/9.4
3.6/2.9 7.1/6.3 10.3/9.6 12.2/11.7
3.7/3.1 6.8/5.9 9.4/8.9 11.9/11.1
2.5/2.0 2.6/1.7
4.2/3.2 6.9/5.9 10.8/9.9
3.6/2.9 7.2/6.4 12.1/11.7
2.6/1.9 2.7/2.1
3.7/2.8 7.1/6.5 10.6/9.7 12.6/11.8
3.5/2.8 6.9/6.1 10.2/9.4 12.2/11.6
2.0/1.4 2.2/1.6
2.4/1.7 2.5/1.9
3.8/3.1 7.2/6.3 10.6/9.8 11.4/10.8 13.6/12.8
3.8/2.9 7.3/6.5 12.4/11.8
2.2/1.7 2.5/2.1
4/3.2 7.1/6.4 12.8/11.9
4.8/3.9 14.6/13.9
2.1/1.7 2.3/1.9
3.8/2.9 6.9/6.1 11.6/10.8
2.2/1.8 2.4/1.9
3.9/3.1 7.2/6.4 10.4/9.5 12.8/11.9
2.0/1.6 2.6/1.9
2.2/1.6 2.5/1.7
4.3/3.8 7.2/6.4 12.3/11.7
3.3/2.5 7.2/6.4 10.3/9.5 13.1/12.6
3.8/3.3 6.9/6.1 10.2/9.4 11.9/10.9 13.3/12.5
3.3/2.6 4.5/3.8
4.0/3.2 6.9/6.2 11.1/10.6
3.3/2.7 7.1/6.3 10.1/9.3 11.4/10.6 13.1/12.6
2.4/2.2 2.5/2.3
4.1/3.6 7.1/6.5 11.5/10.6
Sl. 
No
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
1 2 3 4 5 6 7
  SBR      T/ID                                                                                                  
Days 
CBR 
T/ID
3.6/2.8 7.0/6.2 11.3/10.5
1.9/1.2 2.2/1.7
3.8/2.9 7.2/6.3 11.6/10.8
4.9/4.2 11.1/10.6
2.5/1.3 2.6/1.6
3.6/3.1 7.1/6.8 10.2/9.5 13.2/12.6
2.2/1.5 2.4/1.7
4.2/3.6 13.1/12.6
3.7/3.3 6.9/6.1 11.1/10.8
3.5/2.8 4.6/3.9
4.1/3.8 12.1/11.6
3.3/2.6 7.1/6.2 10.3/9.6 13.6/12.8
2.6/2.0 2.8/2.2
3.8/2.9 7.3/6.5 11.9/11.1
3.9/2.9 7.1/6.6 10.4/9.6 11.8/10.9 13.1/12.6
5.6/4.8 11.7/10.9
2.2/1.6 2.4/1.9
3.6/2.5 12.1/11.6
4.2/3.6 11.2/10.8
2.7/2.0 2.9/2.2
4.5/3.6 14.1/13.6
3.6/2.8 11.1/10.6
2.4/1.7 2.6/1.9
2.0/1.2 2.3/1.6
4.0/3.0 7.3/6.5 12.1/11.6
3.6/2.8 7.0/6.2 10.3/9.5 12.6/11.8
3.8/3.0 6.9/6.1 11.4/10.8
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
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30
31
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33
34
35
36
37
38
39
40
Sl. 
No
1 2 3 4 5 6 7
10.2/9.6 9.1/8.6 8.3/7.6 YES NILL
7.5/6.9 6.9/6.0 5.3/4.6 YES
YES
10.1/9.2 9.1/8.5 8.8/7.9 YES
11.6/11.0 10.2/9.8 7.9/6.9 Yes YES
YES
11.0/10.5 10.1/9.1 8.0/7.3 YES
9.1/8.6 8.5/7.8 8.1/7.2 YES
YES
11.2/10.6 10.1/9.3 7.9/6.9 YES
11.1/10.5 10.2/9.4 8.2/7.6 YES
YES
YES
11.1/10.4 10.2/9.3 8.2/7.5 YES
11.1/10.3 10.1/9.6 8.1/7.6 YES
YES
10.1/9.3 9.2/8.6 6.9/6.2 YES
10.2/9.2 8.8/7.6 7.1/6.4 YES
YES
11.0/10.4 10.2/9.3 8.1/7.4 YES
12.2/11.2 10.1/9.2 9.1/8.6 YES
YES
11.0/10.2 10.4/9.6 7.9/7.1 YES
12.0/11.2 11.2/10.3 9.1/8.2 YES
12.2/11.6 11.0/10.4 9.4/8.4 YES
YES
9.6/8.4 8.5/7.8 6.9/6.1 YES
10.2/9.4 9.5/8.6 7.8/6.9 YES
YES
12.8/12.0 11.4/10.8 10.1/9.3 YES
10.2/9.8 9.6/8.9 8.1/7.6 YES
YES
11.0/10.5 10.2/9.8 8.3/7.6 YES
YES
12.2/11.6 10.1/9.6 9.9/9.1 YES
11.0/10.8 10.2/9.6 8.0/7.3 YES
YES
12.2/11.8 11.1/10.8 8.9/7.9 Yes YES
9.2/8.6 8.5/7.8 7.2/6.5 YES
11.2/10.8 10.6/9.8 8.2/7.6 YES
Phototheraphy                                                                                                                       
Days  
12th
Hour 
SBR
Death
DISCHA
RGED
Exchang
e 
Transfus
ion
REPEAT
SBR   
[last  PT] 
24th 
Hour 
SBR
Sl. 
No
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
1 2 3 4 5 6 7
Phototheraphy                                                                                                                       
Days  
12th
Hour 
SBR
Death
DISCHA
RGED
Exchang
e 
Transfus
ion
REPEAT
SBR   
[last  PT] 
24th 
Hour 
SBR
YES
12.2/11.6 10.1/9.5 9.6/8.8 YES
10.9/10.1 9.2/8.6 8.6/7.8 YES
YES
10.8/10.1 9.2/8.6 8.1/7.5 YES
11.6/10.8 10.2/9.5 8.9/7.9 YES
9.2/8.6 8.3/7.6 6.9/5.9 YES
YES
11.2/10.6 10.8/9.9 9.1/8.2 YES
12.6/11.4 11.2/10.8 9.6/8.8 YES
YES
12.1/11.2 11.2/10.9 9.9/9.1 YES
10.2/9.6 9.8/9.0 8.2/7.6 YES
12.2/11.8 11.1/11.0 9.8/8.9 YES
YES
11.0/10.5 10.4/9.8 8.6/7.9 YES
11.1/10.8 10.1/9.6 8.4/7.6 YES
14.0/13.6 13.1/12.6 11.1/10.5 Yes YES
YES
13.2/12.6 12.9/12.2 11.0/10.6 Yes YES
YES
10.2/9.6 9.6/9.2 7.9/6.9 YES
YES
11.1/10.8 10.4/9.5 8.4/7.6 YES
12.2/11.9 11.0/10.5 9.6/8.9 YES
YES
11.2/10.8 10.2/9.8 8.6/7.9 YES
12.4/11.8 11.3/10.8 9.2/8.6 YES
12.4/11.9 11.6/10.8 10.9/10.1 Yes YES
YES
13.0/12.4 12.4/11.8 11.2/10.6 Yes YES
12.6/11.5 11.9/11.0 10.5/9.2 Yes YES
YES
13.2/12.5 12.6/12.0 11.2/10.7 YES
12.6/11.8 11.5/10.9 10.8/9.9 YES
13.2/12.8 12.6/11.8 11.3/10.6 Yes YES
YES
10.2/9.6 9.3/8.9 8.1/7.6 YES
10.1/9.8 9.2/8.9 8.3/7.7 YES
YES
11.2/10.5 10.6/9.9 8.6/7.7 YES
Sl. 
No
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
1 2 3 4 5 6 7
Phototheraphy                                                                                                                       
Days  
12th
Hour 
SBR
Death
DISCHA
RGED
Exchang
e 
Transfus
ion
REPEAT
SBR   
[last  PT] 
24th 
Hour 
SBR
9.5/8.9 8.5/7.8 6.2/5.6 YES
YES
9.2/8.6 8.3/7.6 7.3/6.2 YES
10.2/9.6 9.1/8.5 8.2/7.4 YES
11.6/10.8 10.5/9.9 7.8/6.9 YES
YES
11.2/10.6 10.1/9.8 8.9/7.9 YES
13.2/12.8 12.8/11.6 11.0/10.6 Yes YES
YES
11.2/10.6 10.8/9.5 7.9/7.1 YES
10.4/9.8 9.5/8.6 7.3/6.8 YES
YES
9.6/8.5 8.4/7.8 6.3/5.8 YES
11.2/10.6 10.2/9.5 7.1/6.4 YES
10.5/9.8 9.2/8.6 7.3/6.5 YES
YES
9.6/8.9 8.2/7.8 6.6/5.8 YES
11.2/10.8 10.1/9.5 8.9/7.9 YES
YES
11.3/10.6 10.2/9.4 8.6/7.8 YES
11.2/10.5 10.3/9.5 8.5/7.8 YES
YES
YES
12.0/11.3 11.2/10.6 10.5/9.8 YES
11.0/10.6 10.1/9.6 9.8/8.9 YES
YES
11.2/10.8 10.2/9.7 8.9/8.1 YES
13.2/12.8 12.1/11.6 11.3/10.5 Yes YES
YES
10.2/9.4 9.3/8.4 7.2/6.9 YES
YES
11.6/10.6 10.2/9.6 6.9/5.9 YES
YES
YES
11.2/10.7 10.4/9.7 7.2/6.8 YES
12.2/11.4 11.6/10.8 9.6/8.8 YES
12.1/11.6 10.6/9.8 9.5/8.6 YES
YES
10.2/9.5 9.5/8.8 7.1/6.3 YES
12.0/11.2 11.2/10.6 7.9/6.9 YES
YES
10.2/9.6 9.6/8.9 7.3/6.5 YES
Sl. 
No
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
1 2 3 4 5 6 7
Phototheraphy                                                                                                                       
Days  
12th
Hour 
SBR
Death
DISCHA
RGED
Exchang
e 
Transfus
ion
REPEAT
SBR   
[last  PT] 
24th 
Hour 
SBR
10.1/9.5 9.5/8.9 7.2/6.5 YES
YES
10.2/9.4 9.2/8.8 6.3/5.5 YES
10.1/9.3 9.1/8.6 6.6/5.8 YES
YES
12.2/11.8 11.0/10.9 9.1/8.5 YES
YES
12.1/11.8 11.2/10.8 8.9/7.9 YES
10.2/9.6 9.6/8.5 7.6/6.9 YES
YES
11.2/10.8 10.6/9.5 8.3/7.6 Yes YES
12.3/11.3 11.0/10.5 8.2/7.5 YES
YES
10.6/10.0 9.2/8.6 7.6/6.9 YES
12.2/11.8 11.1/10.8 9.2/8.5 YES
10.6/9.4 9.5/8.6 7.3/6.5 YES
YES
11.1/10.5 10.6/9.5 8.1/7.4 YES
10.3/9.6 9.4/8.6 7.3/6.5 YES
YES
13.9/12.9 12.6/11.9 10.0/9.2 Yes YES
10.6/9.8 9.1/8.5 6.9/5.9 YES
YES
YES
11.2/10.9 10.6/9.5 7.6/6.8 YES
11.1/10.8 10.2/9.6 8.3/7.6 YES
10.3/9.6 9.6/8.5 6.9/6.1 YES
